WO1995005397A1 - Composition and methods using nitroxides to avoid oxygen toxicity - Google Patents

Composition and methods using nitroxides to avoid oxygen toxicity Download PDF

Info

Publication number
WO1995005397A1
WO1995005397A1 PCT/US1994/009246 US9409246W WO9505397A1 WO 1995005397 A1 WO1995005397 A1 WO 1995005397A1 US 9409246 W US9409246 W US 9409246W WO 9505397 A1 WO9505397 A1 WO 9505397A1
Authority
WO
WIPO (PCT)
Prior art keywords
hemoglobin
nitroxide
based solution
oxygen
stabilized
Prior art date
Application number
PCT/US1994/009246
Other languages
French (fr)
Inventor
Jen-Chang Hsia
Original Assignee
Hsia Jen C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsia Jen C filed Critical Hsia Jen C
Priority to DK94927922T priority Critical patent/DK0714407T3/en
Priority to ES94927922T priority patent/ES2114227T3/en
Priority to JP50714895A priority patent/JP3628019B2/en
Priority to DE69408539T priority patent/DE69408539T2/en
Priority to EP94927922A priority patent/EP0714407B1/en
Publication of WO1995005397A1 publication Critical patent/WO1995005397A1/en
Priority to GR980400805T priority patent/GR3026609T3/en
Priority to HK98106880A priority patent/HK1007858A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Definitions

  • TECHNICAL FIELD This invention relates to the use of nitroxide compounds that are used with macromolecules, including hemoglobin, albumin, immunoglobulins and liposomes to alleviate the toxic effects of oxygen-related species in a living organism.
  • this invention discloses compounds and methods featuring nitroxides associatedwithphysiologically compati ⁇ ble cell-free and encapsulated hemoglobin solutions for use as a red cell substitute and nitroxides associated with other physiologically compatible macromolecules for alleviation and prevention of damage and oxidative stress caused by free radicals.
  • HBOC hemoglobin-based oxygen carriers
  • the red blood cells are the major component of blood and contain the body's oxygen transport system. It has long been recognized that the most important characteristic of a blood substitute is the ability to carry oxygen.
  • the red blood cells are able to carry oxygen because the primary component of the red cells is hemoglobin, which functions as the oxygen carrier.
  • hemoglobin which functions as the oxygen carrier.
  • Most of the products undergoing clinical testing as blood substitutes contain hemoglobin that has been separated from the red blood cell membranes and the remaining constitu ⁇ ents of the red blood cells and has been purified to remove essentially all contaminants. However, when hemoglobin is removed from the red cells and placed in solution in its native form, it is unstable and rapidly dissociates into its constituent subunits.
  • hemoglobin used in a hemoglobin-based oxygen carrier must be stabi ⁇ lized to prevent dissociation in solution.
  • Substantial expenditures in scientific labor and capital were necessary to develop hemoglobin-based products that are stable in solution, and which are stabilized in such a way that the oxygen transport function is not impaired.
  • the ability of the existing hemoglobin-based oxygen carriers to transport oxygen has been well established (See United States Patent Nos.
  • hemoglobin in the red cells binds oxygen molecules as the blood passes through the lungs and delivers the oxygen molecules throughout the body to meet the demands of the body's normal metabolic function.
  • the atmospheric oxygen that most living beings must breathe to survive is a scientific and medical paradox.
  • almost all living organisms require oxygen for life.
  • a variety of toxic oxygen-related chemical species are produced during normal oxygen metabolism.
  • the superoxide anion (•0 ) is an oxygen molecule that carries an additional electron and a negative charge.
  • the superoxide anion is highly reactive and toxic.
  • potentially damaging oxidative stress originates with the superoxide anion being generated by the auto-oxidation of hemoglobin and results from the subsequent conversion of the superoxide anion to toxic hydrogen peroxide in the presence of the enzyme superoxide dismutase (SOD) by the following reaction:
  • red blood cells The presence of the superoxide anion and hydrogen peroxide in the red blood cells is believed to be the major source of oxidative stress to the red cells.
  • red cells Apart from oxygen transport by the hemoglobin continued therein, a less recognized characteristic of the red cells is that they contain a specific set of enzymes which are capable of detoxifying oxygen-related chemical species produced as by-products of oxygen metabolism. Without the protection of these specific enzyme systems, autoxidation of hemoglobin would lead to deterioration and destruction of the red cells. In the body, however, the reserve capacity of the enzyme systems in the red cells protects the body from oxygen toxicity by converting the superoxide anion generated during normal metabolism to non-toxic species and thereby controls the level of oxidative stress. However, if this enzyme system breaks down, the integrity of the red cells will be damaged. A lesion of the gene that produces one of the enzymes in the protective system in the red blood cells will cause an observable pathological condition.
  • glucose-6-phosphate dehydrogenase deficiency a genetic disorder of red cells, is responsible for hydrogen peroxide induced hemolytic anemia. This disorder is due to the inability of the affected cells to maintain NAD(P)H levels sufficient for the reduction of oxidized glutathione result ⁇ ing in inadequate detoxification of hydrogen peroxide through glutathione peroxidase (P. Hochstein, Free Radical Biology & Medicine, 5:387 (1988)).
  • the protective enzyme system of the red blood cells converts the toxic superoxide anion molecule to a non-toxic form in a two-step chemical pathway.
  • the first step of the pathway is the conversion of the superoxide anion to hydrogen peroxide by the enzyme superoxide dismutase (SOD) (See Equation [2] ) .
  • SOD superoxide dismutase
  • the red cells contain another enzyme, catalase, which converts hydrogen peroxide to water as the second step of the pathway (See Equation [3] ) .
  • Red cells are also capable of detoxifying hydrogen peroxide and other toxic organoperoxides using the enzyme glutathione peroxidase which reacts with glutathione to convert hydrogen peroxide and organoperoxides to water.
  • Red cells also contain an enzyme to prevent the build up of the met-hemoglo ⁇ bin produced by the auto-oxidation of hemoglobin.
  • the enzyme met-hemoglobin reductase converts met-hemoglobin back to the native form of hemoglobin. Therefore, in the body, the toxic effects of the auto-oxidation of hemoglobin are prevented by specific enzyme-based reaction pathways that eliminate the unwanted by-products of oxygen metabolism.
  • HBOC hemoglobin-based oxygen carriers
  • the principle method by which the existing HBOC solutions are manufactured is through the removal of hemoglobin from the red cells and subsequent purification to remove all non- hemoglobin proteins and other impurities that may cause an adverse reaction during transfusion (See United States Patent Nos. 4,780,210; 4,831,012; and 4,925,574).
  • the substantial destruction or removal of the oxygen detoxification enzyme systems is an unavoidable result of the existing isolation and purification processes that yield the purified hemoglobin used in most HBOCs.
  • pure hemoglobin instead of isolating and purifying hemoglobin from red cells, pure hemoglobin has been produced using recombinant techniques.
  • recombinant human hemoglobin is also highly purified and does not contain the oxygen detoxification systems found in the red cells.
  • the development of sophisticated techniques to create a highly purified hemoglobin solution is a mixed blessing because the purification processes remove the detrimental impurities and the beneficial oxygen detoxification enzymes normally present in the red cells and ultimately contributes to oxygen-related toxicity.
  • nitric oxide nitric oxide
  • the hemoglobin can also depress the vasorelaxant action of nitric oxide by reacting with nitric oxide to yield the corresponding nitrosyl-heme (NO-heme) adduct.
  • NO-heme nitrosyl-heme
  • deoxy-hemoglobin is known to bind nitric oxide with an affinity which is several orders of magnitude higher than that of carbon monoxide.
  • the antagonism of the vasorelaxant effect of nitric oxide by hemoglobin appears to be dependent on the cell membrane permeability of hemoglobin.
  • hemoglobin did not reverse the effect of L-arginine which is the precursor of nitric oxide.
  • L-arginine which is the precursor of nitric oxide.
  • hemoglobin is the most effective inhibitor of L-arginine induced cyclic-GMP formation mediated by nitric oxide.
  • Hemoglobin is also known to antagonize both endothelium-dependent vascular relaxation ( Martin W. et. al. J. Pharma ⁇ col. Exp. Ther. 232: 708 (1985)) as well as NO-elicited vascular smooth muscle relaxation (Grueter CA. et. al. J. Cyclic. Nucleotide Res. 5:211 (1979)) .
  • Attempts have been made to limit the extravasation and hypertensive effect of hemoglobin by chemically stabilizing, polymerizing, encapsu ⁇ lating, or conjugating the hemoglobin in the HBOCs to prolong the circulation time. Therefore, although the current HBOCs are relatively membrane impermeable and able to transport oxygen, the HBOC solutions do not have the capability of preventing the reaction between superoxide anion and nitric oxide when transfused.
  • An ideal solution to the toxicity problems of the existing blood substitutes would be a hemoglobin-based formulation that combines the oxygen-transport function of the existing HBOCs with the oxygen detoxification function of the red cells.
  • SOD superoxide dismutase
  • Nitroxide(s) stable nitroxide free radicals
  • Nitroxide(s) to provide the oxygen detoxification function of the red cells to hemoglobin-based blood substitutes and to alleviate oxidative stress to avoid biological damage associated with free radical toxicity, including inflammation, post-ischemic reperfusion injury, ionizing radiation, and the aging process.
  • Nitroxides are stable free radicals that are shown to have antioxidant catalytic activities which mimic those of superoxide dismutase (SOD) , and which when existing in vivo. can interact with other substances to perform catalase-mimic activity.
  • SOD superoxide dismutase
  • nitroxides have been used in electron spin resonance spectroscopy as "spin labels" for studying conformational and motional characteristics of biomacromole- cules. Nitroxides have also been used to detect reactive free radical intermediates because their chemical structure provides a stable unpaired electron with well defined hyperfine interactions. In addition, nitroxides have been observed to act as enzyme mimics; certain low molecular weight nitroxides have been identified to mimic the activity of superoxide dismutase (SOD). (A. Samuni et. al. J. Biol. Chem. 263:17921 (1988)) and catalase (R.J. Mehlhorn et. al. , Free Rad. Res. Comm. , 17:157 (1992)).
  • SOD superoxide dismutase
  • nitroxides that are permeable to cell membranes are capable of short-term protection of mammalian cells against cytotoxicity from superoxide anion generated by hypoxan- thine/xanthine oxidase and from hydrogen peroxide exposure.
  • relatively high levels of nitroxide are expected to be well tolerated as nitroxides are known to be relatively safe: for example, the maximum tolerated intraperitoneal dose of TEMPO in mice is 275 mg/kg and the LD 50 is 341 mg/kg.
  • a macromolecule-bound nitroxide will be safer than a free nitroxide.
  • the utility of nitroxide-labelled macromolecule as an antioxidant enzyme mimic therefore, lies in the possibility of achieving high nitroxide levels (and hence activity) with acceptable safety.
  • nitroxides studied to date in living organ ⁇ isms have been relatively low molecular weight compounds which can easily permeate across cell membranes into body tissues.
  • the nitroxides used as enzyme mimics, pursuant to this invention are associated with biological and synthetic macromolecules which may be infused and may remain confined to the vascular compartment.
  • nitroxides are covalently attached to macromolecules to alleviate free radical toxicity while confining the nitroxide to the location, i.e. , the vascular compartment, where their utility in reacting with free radicals is optimized.
  • nitroxides have been covalently bound to hemoglobin molecules for the purpose of studying cooperative oxygen binding mechanisms of hemoglobin, nitroxides have not been used in connection with hemoglobin that is specially formulated for use with blood substitutes. Experimental results are presented below to demonstrate that nitroxides may be attached to stabilized, polymerized, conjugated and encapsu ⁇ lated hemoglobin for use as a blood substitute because the nitroxide reacts with free radicals.
  • nitroxide-labelled hemoglobin with free radicals also suggests that other biologically compatible macromolecules with a substantial plasma half-life may be labelled with nitroxides to advantageously provide resistance to or protection from oxidative stress or toxicity caused by free radical chemical species.
  • nitroxides can be chemically bound to biological macromolecules, including hemoglobin, serum albumin, immunoglobulins, and liposomes.
  • biological macromolecules including hemoglobin, serum albumin, immunoglobulins, and liposomes.
  • this work has generally used nitroxides simply as molecular probes for biophysical research; nitroxide-labeled macromolecules have not been specially formulated for use as therapeutic substances.
  • two techniques for binding the nitroxides to a macromolecule often known as "labelling strategies" are possible.
  • the significance of specific labelling lies in the micro-environ ⁇ ment in which the nitroxide is bound to the macromolecule and the nitroxide's resulting catalytic activity. Specific labelling at a particular ligand binding site or sites will yield a homogeneous product with a more consistent binding site micro-environment and thus a more reliable compound in terms of the catalytic specificity and activity of the nitroxide.
  • compositions and methods using stable nitroxides in connection with biological macromole ⁇ cules and, in particular, with hemoglobin-containing solu ⁇ tions are used with hemoglobin-containing solutions to create several formulations for a blood substitute that will possess the oxygen detoxification function of the red cells.
  • These formulations may be described herein as hemoglobin-based red cell substitutes (HRCs) because the oxygen transport capabil ⁇ ity of the hemoglobin-based oxygen carriers (HBOC) is enhanced by providing the oxygen detoxification function of the body's red cells.
  • HRCs hemoglobin-based red cell substitutes
  • HBOC hemoglobin-based oxygen carriers
  • nitroxide-labelled albumin and nitroxide-labelled immunoglobulins also provide oxygen detoxification by providing a nitroxide covalently attached to a macromolecule possessing a variety of characterized ligand binding sites that is both stable and non-toxic in vivo, and which has a substantial plasma half-life.
  • this invention describes nitroxides that are covalently attached to the inner surface of a container or are attached to an insoluble matrix housed in a filter to be used with an existing HBOC to scavenge toxic oxygen-related compounds before infusion into a patient.
  • the HRCS formula ⁇ tions described herein will alleviate the oxidative stress originating from the generation of the superoxide anion in the existing HBOC solutions, and upon transfusion, will diminish the destruction of nitric oxide, the endothelium- derived relaxing factor (EDRF) . If the destruction of EDRF is prevented, the problem of vasoconstriction and systemic hypertension that are observed when the existing HBOC solutions are infused into a patient will be substantially alleviated.
  • EDRF endothelium- derived relaxing factor
  • the HRCS formulations and nitroxide-labelled macromole ⁇ cules described below retard the formation of toxic oxygen- related species by causing a nitroxide to function as a "superoxide oxidase," an enzyme-like reaction not known to occur in the red cells.
  • the nitroxide prevents the accumulation of the undesirable superoxide anion generated from the auto-oxidation of hemoglobin (See Equation [1]) .
  • the nitroxide-labelled albumin and immunoglobulins similarly function as antioxidant enzyme mimics whose function remains localized in the vascular and interstitial compartments.
  • the superoxide anion is oxidized back into molecular oxygen without proceed ⁇ ing to the formation of hydrogen peroxide. This is accom ⁇ plished in part by creating a storage condition wherein the concentration of nitroxide greatly exceeds that of oxygen. Used in the manner disclosed herein, the nitroxide prevents the cascade of undesirable oxidative reactions that begin with the formation of the superoxide anion. Furthermore, the physiologically compatible HRCS solutions described here will offer advantages over the existing HBOC solutions because the nitroxide will mimic the enzymatic activity of superoxide dismutase and catalase after the formulations described herein are infused into a patient.
  • compositions using nitroxide in connection with a physiologically compatible hemoglobin solutions include: 1) nitroxide attached to a storage container or covalently attached to an insoluble matrix used as a filter, 2) nit ⁇ roxide covalently linked to hemoglobin that is stabilized by chemical or recombinant cross-linking, 3) nitroxide covalent ⁇ ly linked to polymerized hemoglobin, in particular, in 2, 4, and 8 molar equivalents of nitroxide, 4) nitroxide co- encapsulated with hemoglobin inside a liposome or intercalat ⁇ ed into a liposome membrane, (5) nitroxide covalently bound to conjugated hemoglobin, (6) nitroxide covalently bound to albumin, and (7) nitroxide covalently bound to immunoglob ⁇ ulins.
  • HRCS based on the co-encapsulation of a membrane- impermeable nitroxide with hemoglobin is disclosed.
  • the methods of preparing the above formulations are described as are methods for producing nitroxide-containing filters and containers for the storage and detoxification of an existing HBOC.
  • compositions using nitroxide in connection with human serum albumin or recombinant albumin include:
  • compositions using nitroxide in connection with immunoglobulins include a nitroxide labelled hapten or antigen bound to an immunoglobulin specific for the hapten or antigen.
  • Figures 1A and IB show the electron spin resonance spectra of 4-amino-TEMPO labelled o-raffinose polymerized hemoglobin recorded on (A) day 1 and (B) day 30 (TEMPO: 2,2,6,6 tetramethylpiperidine-1-oxyl) .
  • Figure 1C is the spectra of the sample in Figure 1A diluted with equal volume of unlabelled hemoglobin recorded on day 1.
  • Figure ID is the sample in Figure 1C recorded on day 30.
  • Figures 2A and 2B are, respectively, the electron spin resonance spectra demonstrating covalent attachment of 4- (2- bromoacetamido) -TEMPO to ⁇ -aminohexyl-agarose and 4-amino- TEMPO to 1,4-bis(2:3-Epoxypropoxy) butane-activated agarose.
  • Figures 3A and 3B are electron spin resonance spectra demonstrating successful covalent attach ⁇ ment of 4- (2-Bromoacetamido) -TEMPO and 3-maleimido-PROXYL to 3,5-bis-bromosilicyl-bisfumarate (DBBF) cross-linked or diaspirin cross-linked human hemoglobin.
  • DBBF 3,5-bis-bromosilicyl-bisfumarate
  • Figure 4A is an ESR spectra of 4- (2-bromoacetamido) - TEMPO.
  • Figure 4B is an ESR spectra of 4- (2-bromoacetamido) - TEMPO-labelled HBOC.
  • Figure 4C is an ESR spectra of 15 ND 17 TEMPOL in Lactated Ringer's solution recorded at room temperature.
  • Figure 5 is an ESR spectra of 4- (2-bromoacetamido) -TEMPO- labelled HBOC with different molar ratios of nitroxides to Hb; Fig. 5A 2:1, Fig. 5B 4:1 and Fig. 5C 8:1.
  • the instrument sensitivity were decreased proportionately from Fig. 5A to Fig. 5B to Fig. 5C to record the spectra so that the center peak (Mo) would be shown to have similar peak height.
  • Figure 6 is an ESR spectrum of a mixture of 4- (2-bromo ⁇ acetamido) -TEMPO labelled HBOC and 15 ND 17 -TEMPOL wherein the center peak (see down arrow) of the former and the high field peak (see up-arrow) of the latter were adjusted to similar intensity. This is a superimposition of ESR spectrum from Fig. 4B and Fig. 4C.
  • Figure 7 is a plasma half-life of 4- (2-bromoacetamido) - TEMPO-labelled HBOC in mouse.
  • Fig. 7A is the ESR spectrum of the nitroxide signal recorded from the mouse tail approxi ⁇ mately 10 minutes after i.v. infusion of 0.5 ml of the sample shown in Fig. 6.
  • Fig. 7B is the time dependent (scan time 30 minutes) decrease in the center peak (Mo) signal intensity of Fig. 7A recorded at 10 times of the instrument sensitivity.
  • Fig. 7C is a continuation of Fig. 7B at the end of its scan.
  • Figure 8 is a plasma half-life of a mixture of 4- (2- bromoacetamido) -TEMPO-labelled HBOC (8g/dl of Hb and 8:1 TEMPO to Hb) and 15 ND 17 TEMPOL (0.5 ml in a 32 g. mouse) recorded from the mouse tail with a cannula for immediate recording of the infused nitroxides.
  • the ESR spectrum of the sample prior to injection is shown in Fig. 6.
  • Fig. 8A is a series of 5 ESR spectrum recorded at 0.5 minute intervals, the magnetic field strength was increased by 2 Gauss in between each scan to display the decrease in signal intensity as a function of time.
  • Fig. 8B is the continuation from Fig. 8A of repeated recording of a series of 6 ESR spectrum at the same time intervals except that the magnetic field strength was decreased by 2 Gauss in between each scan.
  • Figures 9A and 9B are electron spin resonance spectra demonstrating 4-amino-TEMPO labelled and o- raffinose cross-linked and polymerized human hemoglobin and 3-maleimido-PROXYL labelled DBBF-hemoglobin polymerized with glutaldehyde.
  • Figures 10A, 10B, and IOC respectively are electron spin resonance spectra of liposome encapsulated human hemoglobin containing (A) 3-DOXYL-cholestane (B) 16-DOXYL-stearic acid and (C) both 3-DOXYL-cholestane and 16-DOXYL-stearate.
  • Figure 11 is the electron spin resonance spectrum of nitroxide-labelled hemoglobin labelled with 4-amino-TEMPO and conjugated with dextran.
  • Figure 12 is an embodiment of a filter cartridge that contains a solid matrix to which a nitroxide is bound and through which a hemoglobin-containing solution may be passed.
  • hemoglobin is used generally herein to describe oxy-, carboxy-, carbonmonoxy-, and deoxy-hemoglobin except as otherwise noted by the context of the description.
  • the hemoglobin used with this invention may be human, recombinant or animal in origin and is obtained and purified by known techniques.
  • the hemoglobin may be covalently bound to pyridoxal groups of pyridoxal-5' -phosphate or ring opened adenosine triphosphate (o-ATP) by reaction with the aldehyde groups and cross-linked derivatives of hemoglobin.
  • the cross-linked derivatives may include polyfunctional, hetero- bifunctional and homobifunctional cross-linking regents such as dialdehyde, polyaldehyde, diepoxide, polyepoxide, activat ⁇ ed polycarboxyl and dicarboxyl groups, for example, 3,5-bis- bromosilicyl-bisfumarate, and TEMPO succinate or TOPS See (U.S. Patent No. 4,240,797) cyclodextrans and their anionic (e.g.. sulfate) cross-linked hemoglobin as well as polymer ⁇ ized hemoglobin. All hemoglobin solutions described herein for use with this invention are physiologically compatible. The hemoglobin solutions are cell-free to remove pyrogens, endotoxins, and other contaminants.
  • cross-linking regents such as dialdehyde, polyaldehyde, diepoxide, polyepoxide, activat ⁇ ed polycarboxyl and dicarboxyl groups, for example, 3,5
  • nitroxide is used herein to describe stable nitroxide free radicals, their precursors, and their deriva ⁇ tives thereof including the corresponding hydroxylamine derivative where the oxygen atoms are replaced with a hydroxyl group and exist in hydrogen halide form.
  • chloride salt form of the hydroxylamine derivatives are preferred.
  • the unpaired electron of a nitroxide is stable in part because the nitrogen nucleus is attached to two carbon atoms which are substituted with strong electron donors. With the partial negative charge on the oxygen of the N-0 bond, the two adjacent carbon atoms together localize the unpaired electron on the nitrogen nucleus.
  • Nitroxides may have either a heterocyclic or linear structure.
  • the fundamental criterion is a stable free radical. Structurally, nitroxides of the following formula are preferred where R x - R 4 are electron donors and A is the remaining members of a heterocyclic ring.
  • A represents the remaining carbon atoms of a 5-membered (pyrrolidinyl or PROXYL with one double bond, i.e.. pyrroline) or a 6-membered (piperidinyl or TEMPO) heterocyclic structure and in which one carbon atoms may be substituted with an oxygen atom (oxazolinyl or DOXYL) and certain hydrogen atoms may be substituted with up to two bromine atoms.
  • stable isotopes may be utilized (e.g., N 15 , deuterium) . Substitution at the carbons should be such that the unpaired electron is maintained substantially in a 7ip orbital configuration.
  • R x through R 4 are alkyls (straight and branched chain) or aryl groups but are preferred to be methyl or ethyl groups.
  • the substituent groups on the alpha carbons in any nitroxide should be strong electron donors to enhance stability, thus methyl (CH 3 ) groups or ethyl (C 2 H 5 ) groups are preferred although other longer carbon chain species could be used. In practice, stearic considerations may limit the scope of the nitroxide compounds that are practical and economical.
  • the preferred nitroxides used with this invention include nitroxides having the following structure:
  • nitroxides which can be employed in this invention are structurally diverse because the requisite property of the nitroxides is their ability to influence the course of the superoxide anion cascade in HRCS by mimicking the superoxide oxidase, superoxide dismutase, and catalase activities without substantially being consumed in the process. Although a wide variety of nitroxides may be used with this invention, the nitroxide should be physiologically acceptable at a minimum concentration required to alleviate oxygen toxicity in the HRCS. In assessing an operative species, it is noteworthy that the relatively low toxicity of nitroxides has encouraged their development as contrasting agent in NMR imaging (See U.S. Patent Nos. 4,834,964; 4,863,717; 5,104,641) .
  • purified hemoglobin compositions contain at least 99% hemoglobin by weight of total protein, a total phospholipid content of less than about 3ug/ml, less than lug/ml of either phosphatidyl- serine or phosphatidylethanolamine and an inactive heme pigment of less than 6%.
  • the purified hemoglobin solutions which are useful in this invention can be prepared using a variety of conventional techniques, including but are not limited to, those disclosed in Cheung et. al., Anal Biochem 137:481-484 (1984), De Venuto et. al. , J. Lab. Clin. fertil. 89:509-516 (1977), and Lee, et. al. , Vith International Symposium on Blood Substitutes, San Diego, CA Mar. 17-20 Abstract H51 (1993) .
  • the purified hemoglobin solutions used in this invention should be essentially free of oxygen.
  • Hemoglobin in solution may be deoxygenated by admixture with a chemical reducing agent which causes the hemoglobin to release oxygen and to be maintained in a substantially deoxygenated state.
  • a pre ⁇ ferred method for deoxygenating a hemoglobin solution is performed by exposing a hemoglobin solution to an inert, essentially oxygen-free gas, such as nitrogen or carbon monoxide to cause removal of bound oxygen from the hemoglobin and conversion of the hemoglobin in solution to a form such as deoxy-hemoglobin or carbonmonoxy-hemoglobin that lacks oxygen.
  • hemoglobin may be exposed to a vacuum or gas through a membrane that is permeable to oxygen yet impermeable to hemoglobin.
  • a hemoglobin solution may be passed through a diffusion cell having a membrane wall along which hemoglobin flows and through which oxygen is capable of passing, but hemoglobin is not.
  • Inert gas is circulated along the side of the membrane wall opposite the hemoglobin solution causing the removal of oxygen and the conversion of the hemoglobin in solution to the deoxygenated state.
  • the deoxy-hemoglobin is maintained in an essentially oxygen-free environment during nitroxide labelling, cross-linking, polymerization, or conjugation.
  • a nitroxide is covalently attached to the hemoglobin.
  • nitroxide Normally at least one, and preferably more than one, nitroxide will be cova ⁇ lently attached to a single hemoglobin molecule.
  • the nitroxide may be covalently attached to the hemoglobin at any of several sites on the hemoglobin molecule including:
  • a nitroxide may also be bound to any residual aldehyde, epoxy, or activated carboxyl groups of a divalent- or a multivalent-cross-linker involved in the cross-linking and polymerization of hemoglobin or at any residual reactive groups on an agent such as dextran (Dx) or hydroxylethyl- starch (HES) or polyoxyethylene (POE) used to conjugate hemoglobin.
  • Dx dextran
  • HES hydroxylethyl- starch
  • POE polyoxyethylene
  • the hemoglobin in an HBOC solution is slowly auto- oxidized by oxygen to form met-hemoglobin and the superoxide anion.
  • the superoxide anion thus formed will reduce the nitroxide to a hydroxylamine derivative, and the superoxide anion will be oxidized to form molecular oxygen by the following reaction.
  • Equation [4] The conversion of superoxide anion to molecular oxygen described in Equation [4] prevents the accumulation of superoxide anion and the subsequent formation of hydrogen peroxide.
  • This activity described herein as a "superoxide oxidase" activity, will be most effective when the initial oxygen content in the composition is kept to a minimum, the composition is stored in an essentially oxygen free environ ⁇ ment and the nitroxide concentration is sufficient to prevent the formation of superoxide anion and hydrogen peroxide. Therefore, storage of the HRCS in an essentially oxygen-free container is preferred.
  • Container systems that permit a solution to be stored in an oxygen free environment are well known because many non- hemoglobin based intravenous solutions are sensitive to oxygen.
  • a glass container that is purged of oxygen during the filling and sealing process may be used.
  • flexible plastic containers are available that may be enclosed in an overwrap to seal against oxygen. Basically, any container that prevents oxygen from interacting with hemoglobin in solution may be used.
  • an o-raffinose polymerized hemoglobin solution that has been labelled with 4-amino-TEMPO is stored in its oxygenated state in a sealed glass container ( Figure 1A) .
  • Figure 1A the rate of superoxide anion and met-hemoglobin formation in solution is sufficiently rapid that the conver ⁇ sion of the nitroxide to its hydroxylamine derivatives may be conveniently monitored (See Equation [4] and compare Figures 1A and IB) .
  • Equation 4 represents that the conversion of nitroxide to its diamagnetic hydroxyl derivative is coupled to the conversion of the superoxide anion back to molecular oxygen. The experimental evidence in support of such a conversion is shown in Figures 1A and IB.
  • the "superoxide dismutase" activity of a nitroxide in an HBOC solution is demonstrated by showing the reconversion of the hydroxylamine derivative back to a nitroxide (See Equation [5] together with Equation [4] ) . Knowing that under the experimental conditions described in Figures 1A and IB the nitroxide is fully converted to hydroxylamine (See Equation [4] ) , the nitroxide may be regenerated by simply providing more superoxide anion as shown in Equation 5. To demonstrate this reaction mechanism, the relative concentra ⁇ tion of hemoglobin (and thus superoxide anion) to the nitroxide is increased by diluting the sample in Figure 1A with an equal volume of unlabelled hemoglobin.
  • the number of nitroxide molecules per hemoglobin molecule may be in the range of approximately 1-40 and for specific labelling is most preferably about 2. However, the nitr ⁇ oxide-hemoglobin ratio should be kept to a minimum due to pharmacokinetic, toxicological and immunological consider ⁇ ations.
  • a nitroxide such as 3-maleimido-PROXYL is covalently bound to hemoglobin in solution by first preparing a lOOmM solution of the nitroxide in ethanol as the carrier solvent. Two(2) molar equivalents of the nitroxide to hemoglobin was added directly with mixing to a DCL-Hb
  • nitroxides have been covalently bound to hemoglobin to study the cooperative oxygen binding properties of the hemoglobin molecule itself.
  • nitroxides have not been used with stabilized, i.e.. cross-linked, or polymerized, encapsulated, or conjugated hemoglobin solution that are physiologically compatible.
  • the known chemistry of hemoglobin and nitroxides suggests that it is possible to perform similar nitroxide-labelling of hemoglobin that has been chemically cross-linked or cross-linked through recombi ⁇ nant techniques by selecting an available site on the hemoglobin molecule that is not blocked by the particular compound used to stabilize, polymerize, or conjugate the hemoglobin molecule(s).
  • nitroxides to these stabilized and polymerized hemoglobin- based oxygen carriers is described below in the context of the second, third, and fifth preferred embodiments to demon ⁇ strate that the oxygen detoxification function of this invention is applicable to the existing hemoglobin solutions.
  • the nitroxide-labeling technology demonstrated here in the example of nitroxide-HBOC is readily applied to the production of other nitroxide-labelled macromolecules with useful antioxidant enzyme-mimetic activities, for example nitroxide-labelled serum albumin and nitroxide-labelled immunoglobulin.
  • forms of serum albumin which can readily be labelled by nitroxide by this technology are monomeric (normal) albumin, and albumin homodimers, oligomers, and aggregates (microspheres) .
  • the antioxidant enzyme mimic effect of a nitroxide- labelled macromolecule, hemoglobin, or the other appropriate macromolecules described here, has utility in other applica ⁇ tions, medical or otherwise, where antioxidant catalysis is useful.
  • this invention may alleviate the adverse physiological effects caused by oxygen toxicity that are observed with the existing formulations.
  • the container used with the hemoglobin-containing solutions that are the subject of this invention should be physiologically compatible having similar characteristics as any container to be used with intravenous fluids.
  • glass or a biocompatible plastic is suitable.
  • the container should be oxygen free and capable of being sealed to exclude oxygen.
  • a tradi ⁇ tional stopper and closure means is sufficient.
  • some of the flexible plastic containers currently available are oxygen permeable. In this case, a foil overwrap or other sealing mechanism may be used to prevent oxygen from contact ⁇ ing the hemoglobin in solution.
  • Nitroxide-containing polymers can be created by a number of techniques based on generally known principles of polymeriza ⁇ tion as long as the stability of the free radical is main ⁇ tained in the polymerization process.
  • an HBOC container may be modified to contain a coating layer of a substance that can bind a nitroxide, such as hydrophilic hydrazide groups which will react with the ketone or the aldehyde group of a nitroxide to form stable hydrazone derivatives.
  • a nitroxide such as hydrophilic hydrazide groups which will react with the ketone or the aldehyde group of a nitroxide to form stable hydrazone derivatives.
  • the coating reaction is straight forward.
  • the nitroxide (lOOmM) in acetate buffer at pH 5.0 is added to a hydrazide activated plastic container to facilitate the formation of a hydrazone linkage.
  • a physiologically com ⁇ patible solution is added.
  • This solution may be a stabilized and purified HBOC or the HRCS disclosed herein, but could also include any intravenous colloid or crystalloid solution that is desirable to co-infuse with hemoglobin.
  • the solution is then maintained in an essentially oxygen-free environment.
  • a filter-type cartridge with a luer lock inlet and outlet, containing a gel or solid matrix upon which a nitroxide is immobilized may be used to remove reactive oxygen-derived reactive species while the hemoglobin solution passes through the cartridge.
  • the nitroxide is bound to a soft- or hard-gel matrix through which the HBOC passes, functioning essentially as a sterile in-line filter, prior to infusion.
  • a variety of methods to attach small ligands, such as nitroxide, to a solid matrix are well known in the art of affinity chromatography, as are the techniques to chemically modify glass and plastic surfaces.
  • matrices that are compatible with sterile solutions included ing agarose gel, polysulfone-based material, latex, and others.
  • the solid matrix is covalently linked with a nitroxide and contained in a filter housing or other such apparatus such that a hemoglobin solution can flow through the apparatus and be brought into contact with a nitroxide while being infused into a patient.
  • a practical approach is to use a commonly available activated agarose gel as the matrix and contain the gel in a sterile luer lock cartridge. The cartridge is then simply inserted in the fluid administration line during the transfusion of a solution containing hemoglobin.
  • the structure that comprises the filter housing in which the nitroxide and through which hemoglobin is passed can be provided by a variety of known structures. Referring now to Figure 12, housing 1 contains a nitroxide-labelled agarose gel.
  • a 4-bromoacetamido-TEMPO labelled ⁇ -aminohexyl- agarose See Figure 2A
  • a 1,4-bis(2,3-epoxypropoxy)butane agarose coupled with 4-amino-TEMPO See Figure 2B
  • the intravenous transfusion line containing a hemoglobin solution containing a hemoglobin solution would be connected to the luer inlet 2 allowed to enter the housing 1 wherein the hemoglobin solution would encounter the nitroxide bound to the matrix 4 to remove the toxic oxygen-related species.
  • the hemoglobin solution would then pass out of the cartridge through the luer outlet 3 and would be directly transfused into a patient.
  • the electron resonance spectrum of 4-amino- TEMPO labelled epoxy-agarose is shown in Figure 2A. Alterna ⁇ tively, an ⁇ -aminohexyl-agarose may be reacted with 4- (2- bromoacetamido) -TEMPO to form TEMPO labelled agarose.
  • the electron spin resonance spectrum is shown in Figure 2B.
  • the cartridge labelled with 4-amino-TEMPO prepared by circulating a lOOmM 4-amino-TEMPO (Sigma Chem. Co.) in a Lactated Ringers solution through an aldehyde AvidChrom Cartridge (Unisyn Tech. Inc.) at room temperature for one hour followed by the reduction with sodium cyanoborohydride for six (6) hours.
  • the interior of the cartridge housing is thoroughly washed with Lactated Ringers.
  • the cartridge labelled with 3-amino-PROXYL may be simi ⁇ larly prepared by substituting 4-amino-TEMPO with 3-amino- PROXYL according to the procedure described above. II. Second Preferred Embodiment -- Nitroxide-Labelled
  • hemoglobin is intramolecularly stabilized by chemical or recombinant cross-linking of its subunits.
  • "Stabilized" hemoglobin is referred herein to describe hemoglobin monomers that are stabilized by chemical or recombinant cross-linking and also to describe dimers, trimers, and larger oligomers whose constituent hemoglobin molecules are stabilized by cross-linking with cyclodextrans and their sulfated derivatives.
  • a preferred technique and best mode for attaching nitroxide to stabilized hemoglobin is by the covalent attachment of the nitroxide to the S-93 sulfhydryl groups of the two S-chains of stabilized hemoglobin.
  • hemoglobin-based oxygen carriers have been developed that are stabilized through chemical cross-linking with DBBF, diaspirin cross- linked hemoglobin and hemoglobin that is stabilized and oligomerized with o-raffinose.
  • the ring opened sugars described in my United States Patent No. 4,857,636 yield polyvalent aldehydes derived from disaccharides, oligosaccharides, or, preferably, tri- saccharides such as o-raffinose. These compounds function both to provide intramolecular stabilization (cross-linking) and intermolecular polymerization.
  • the polyvalent aldehydes may be used to produce "stabilized" hemoglobin as defined above without polymerization.
  • a nitroxide may be covalently bound to the stabilized hemoglo ⁇ bin or the polymerized hemoglobin. Therefore, the hemoglo ⁇ bin-based solutions that are stabilized using the polyvalent aldehydes are considered in the present embodiment as a "stabilized" hemoglobin and in the subsequent embodiment as a polymerized hemoglobin.
  • DBBF-Hb is reacted with two types of nitroxides (TEMPO and PROXYL) which contain two types of sulfhydro group specific functional groups and have the following structural formula:
  • DBBF-Hb is prepared by cross-linking purified deoxygenat ⁇ ed hemoglobin in solution with bis(3,5 dibromosalicyl)fuma- rate by known techniques, and the resulting product is purified by column chromatography.
  • the covalent attachment of 3-maleimido (2,2,5,5 -tetramethyl pyrrolidine-N-Oxyl) [3- maleimido-PROXYL] is accomplished by adding 2 molar equiva ⁇ lents of this nitroxide using methanol as the carrier solvent at a concentration of approximately lOOmM of 3-maleimido- PROXYL to 1ml of DBBF-Hb at a concentration of approximately 8 g/dl in Lactate Ringers.
  • the DBBF-Hb is allowed to react at 22-23°C for approximately 30 minutes with mixing.
  • the extent of cross-linking is estimated from the percent disappearance of the electron spin resonance signal intensity of the unreacted nitroxide.
  • the reaction mixture was washed three (3) times with a 10 volume excess of Lactated Ringers using a Filtron stire cell with a 30 kilodalton cut-off nominal molecular weight limits (NMWL) polyethylene sulfone (PES) membrane (Filtron Technology Co.).
  • NMWL nominal molecular weight limits
  • PES polyethylene sulfone
  • Figure 3A shows the electron spin resonance spectra of 4- (2-bromoacetamido) -TEMPO labelled DBBF-Hb.
  • the electron spin resonance spectrum of DBBF-Hb that is similarly labelled with 3-maleimido-PROXYL is shown in Figure 3B.
  • the nitroxide is covalently linked to the lone sulfhydro group on the two ⁇ -globin chains of hemoglobin.
  • the nitroxide to hemoglobin-bound oxygen ratio is approximately 200 to 1 at 99.00% deoxy-hemoglobin because there are two nitroxides attached to the two ⁇ -globin chains of the hemoglobin.
  • the deoxygenated HRCS picks up oxygen in the lung and the nitroxide to hemoglobin-bound oxygen ratio becomes approxi ⁇ mately 1 to 2 at 100% oxygenation because there are four oxygen molecules bound to the four globin chains of the hemoglobin with the two nitroxides remaining on the /3-globin chains.
  • DBBF-Hb may also be covalently labelled with a spacer group (e.g., an extra methyl group) between the maleimido and PROXYL moieties (i.e., 3-maleimidomethyl-PROXYL) which would exhibit a resonance spectrum similar to that of Figure 3B.
  • a spacer group e.g., an extra methyl group
  • nitroxides may be covalently at ⁇ tached to specific amino-groups in the DPG binding site (e.g., jS-Val-1 /3-Lys-82 and oc-Lys-99) or may be attached to the remaining 40-plus surface lysine e-amino groups on hemoglobin.
  • Isothiocyanate derivatives of the TEMPO and PROXYL nitroxides are also reactive with the amino group.
  • 4-isothiocyanate-TEMPO may be added to hemoglo ⁇ bin at a molar ratio of approximately 10:1. Resonance spectrum (not shown) of hemoglobin labelled with this nitroxide at other sites is similar to that shown in Figure 3A.
  • DBBF-Hb The ability to attach nitroxides at several sites of DBBF-Hb suggests that recombinant hemoglobin that is stabi ⁇ lized with alpha-globin dimers (D. Looker et.al. NATURE 356:258 (1992)) may be similarly labelled with a nitroxide. It is also possible to prepare a DBBF analogue of a nitroxide labelled cross-linking agent such as a TEMPO labelled succinate (See U.S. Patent No. ' 4,240,797) .
  • a nitroxide labelled cross-linking agent such as a TEMPO labelled succinate
  • Figure 4 is ESR spectra of (A) 2- (bromoacetamido) -TEMPO, (B) 2- (bromoacetamido) -TEMPO-labelled HBOC and (C) 1S ND 17 TEMPOL (TEMPOL: 4-hydroxy-2,2,6,6-tetramethylpiperidine-l- oxyl) in Lactated Ringer's solution recorded at room tempera ⁇ ture.
  • the difference in Figure 4A and 4B represents the difference in the mobility of a small molecular weight nitroxide to that of a nitroxide covalently attached to a macromolecule such as hemoglobin.
  • Figure 4C shows that a stable isotope nitrogen 1S N with a nuclear spin of 1/2 yields two resonance peaks and that natural-isotopic 14 N with a nuclear spin of 1 yields three resonance peaks (compare (4A to 4C) .
  • the separa ⁇ tion of these resonance peaks is used to demonstrate the enzyme-mimic and in vivo and in vi tro oxidation/reduction reactions of small and macromolecular weight nitroxides.
  • Nitroxide labelled HBOC with different molar ratios of nitroxide to hemoglobin are prepared as follows. 2, 4, and 8 molar equivalents of 4- (2-bromoacetamido) -TEMPO, were added as solid powder directly into three separate 15 ml Vacutain- ers in a clean hood. After replacing the rubber septum, 4- (2-bromoacetamido) -TEMPO was subsequently dissolved in 200 ul chloroform. The Vacutainers were then connected to high vacuum (5 mm Hg) via a 27 gauge needle through the rubber septum and the chloroform was removed leaving a thin film of 4- (2-bromoacetamido) -TEMPO coating the lower half of the Vacutainer.
  • the solutions were allowed to react at room temperature with intermittent vortex mixing at approximately 5 minute intervals for 1/2 hour (not all solids were dissolved in the 4 and 8 molar ratios of nitroxide to hemoglobin) , the Vacutainers were then left at 4 degrees C in a refrigerator over night. Vortex mixing at room temperature was resumed the next morning for another 1/2 hour until all solids of 4- (2-bromoacetamido) - TEMPO had visually disappeared from the surface of the Vacutainer.
  • reaction mixtures and the control were then trans ⁇ ferred to a sterile dialyzing tube and dialyzed against Lactated Ringers until no unlabelled free 4- (2-bromoacet ⁇ amido) -TEMPO electron spin resonance (ESR) signals could be detected.
  • ESR electron spin resonance
  • the ESR spectra of 4- (2-bromoacetamido) -TEMPO- labelled HBOC at 2, 4, and 8 molar equivalents 4- (2-bromo ⁇ acetamido) -TEMPO to Hb are shown in Figures 5A-5C respective- ly.
  • the ESR spectra are essentially the same with or without dialysis indicating the covalent labeling is quanti ⁇ tative.
  • the two SH- groups on the beta globulin chains appear to be the site of covalent attachment in the case of HBOC (this can be confirmed by selective blocking of 4- (2- bromoacetamido) -TEMPO labeling with N-ethyl-maleimide or globulin chain analysis by reverse phase HPLC) .
  • the ESR signal intensity (peak Mo) ratios for 2, 4, and 8 are in approximately the same ratio as the spectra were recorded at proportionately decreasing instru ⁇ ment sensitivity.
  • the preferred molar of nitroxide to hemoglobin in the blood substitute formulations is 8:1 as described below.
  • TEMPOL (indicated by the up-arrow) were adjusted to similar intensity.
  • the separation of the resonance peaks permits the simul ⁇ taneous monitoring of free radical or enzyme mimic activities involving the small molecular weight nitroxide (TEMPOL) and its macromolecular conjugate in both in vi tro and in vivo (murine) reactions.
  • the in vivo plasma half- life of the two nitroxides was compared by referring to the unique spectral characteristics of the different nitroxides.
  • the in vivo ESR studies of hemoglobin-based solutions, on the mouse were performed using a nitroxide to hemoglobin ratio of 8:1 (see Fig. 5C) to take advantage of its high ESR signal intensity.
  • the approximate plasma half-life of a small molecular "weight nitroxide ( 15 ND 17 -TEMPOL see Fig. 4C) and a large molecular weight 4- (2-bromoaceta ⁇ mido) -TEMPOL-labelled HBOC (see Fig. 4B) are determined by preparing a mixture of the two and adjusting the ESR signal intensity to be approximately the same (see Fig. 6) .
  • 0.5 ml of the mixture was injected under anesthesia into a distended mouse tail vein under a heat lamp.
  • the mouse tail was inserted into an ESR cavity and the spectrum was recorded within 10 min. after injection (see Fig. 7A) .
  • the tail vein of female CH3 mouse was cannulated under anesthesia with 80% nitrous oxide, 20% oxygen, and 3% isofluorane. Under a heat lamp the mouse tail vein became visibly distend ⁇ ed, a cannula consisting of a 30 gauge hypodermic needle attached to a one foot length of polyethylene tubing was inserted into the tail vein and held in place by cyanoacry- late glue. For in vivo ESR measurements, the cannulated mouse was transferred under anesthesia to a 50 ml conical centrifuge tube modified to allow the tail to protrude from the conical end and to allow a continuous flow of anesthetic gas from the opening end of the tube.
  • the tail was inserted into a plastic tube which was then fitted into a TE 102 cavity.
  • the cannula was flushed periodically with heparin (100 unit/ml) to ensure patency.
  • the cannula was near the root of the tail and was kept outside of the ESR cavity so that a pure signal from the tail could be measured immediate ⁇ ly after bolus injection.
  • 0.5 ml of samples (see Fig. 8) were injected via the cannula and the spectrometer was set for a repeat scanning mode at 1/2 min. intervals (see Figs. 8A and 8B) .
  • Fig. 8A the magnetic field was increased by two Gauss
  • Fig. 8B the Fig. 8B
  • Fig. 8B shows that the nitroxide-labelled to macromolecules such as HBOC has considerably longer plasma half-life as compared to small molecular weight nitroxide (e.g.. 15 ND 17 -TEMPOL) .
  • the rapid phase appears to involve the free radical (e.g. superoxide) oxidation of the nitroxide to its oxoammonium cation intermediate followed by the reduction of the oxoammonium cation to its stable hydroxylamine derivative of the nitroxide.
  • free radical e.g. superoxide
  • reduction involves the participation of either one or two reducing equivalents (e.g. NADH) present in the vascular compartment.
  • NADH reducing equivalents
  • the reduction of nitro ⁇ xide to its hydroxylamine would lead to a rapid reduction in ESR signal intensity, in the case of 8:1 molar ratio of 4- (2-bromoacetamido) -TEMPO- labelled HBOC represents approximately 25% of the 4- (2-bromoacetamido) -TEMPO on the HBOC.
  • This phase involves both small molecule and macromolecular nitroxide.
  • the slow phase appears (see Figure 8B) to represent the antioxidant enzyme-mimic activities of the remaining 75% of 4- (2-bromoacetamido) -TEMPO on the HBOC in accordance with the reaction mechanism wherein the nitroxide is involved in the cyclic- free radical reactions for example the SOD-mimic reaction.
  • the slow rate of decrease of the ESR signal intensity can be attributable primarily to the reaction mechanism described above and secondarily to the decrease in
  • the preferred method of introduc ⁇ ing a nitroxide to a solution of polymerized hemoglobin is again by covalently attaching a nitroxide to the ⁇ -93 sulfhydryl groups of the two /S-globin chains of hemoglobin. These sulfhydryl groups are not known to be involved in the stabilization or polymerization processes. Consequently, the nitroxide is preferably covalently attached to hemoglobin before the stabilization and polymerization of the hemoglobin monomers.
  • nitroxide is covalently attached to DBBF-Hb according to the procedure described in the second embodiment above, followed by polymerization with glutaldehyde according to the procedure described in Sehgal et. al. U. S. Patent No. 4,826,811.
  • Figure 4B is an electron spin resonance spectra of the DBBF-Hb labelled with 3-maleimido-PROXYL and polymer ⁇ ized with glutaldehyde.
  • DBBF-Hb that is polymer ⁇ ized with glutaldehyde may be labelled with 4-(2-bromo- acetamido) -TEMPO by the same method.
  • a polymerized hemoglobin intermediate such as a glutaldehyde-polymerized, an o- raffinose-polymerized, or an o-cyclodextran-polymerized hemoglobin intermediate that contains unreacted aldehyde groups, may be used for covalent attachment of either 4- amino-TEMPO or 3-amino-PROXYL via reductive amination to yield a nitroxide-labelled hemoglobin polymer.
  • reduc ⁇ tive amination the sequence and timing of the reaction are important.
  • the 4-amino-TEMPO is added to glutaldehyde- polymerized hemoglobin after completion of polymerization, but prior to the reduction reaction that results in covalent attachment of the nitroxide to the polymerized hemoglobin.
  • the nitroxide labelling of a o-raffinose poly ⁇ merized hemoglobin may be accomplished by the addition of either 4-amino-TEMPO or 3-amino-PROXYL prior to reductive amination.
  • 4-amino-TEMPO labelled o-raffinose polymerized hemoglobin is prepared according to the procedure described in my United States Patent No.
  • hemoglobin may be cross-linked and polymerized using polyvalent aldehydes derived from disaccha- rides or ring-opened sugars including, oligosaccharides, or preferably, trisaccharides such as o-raffinose. Likewise, monosaccharides may be used to stabilize and polymerize hemoglobin although the higher molecular weight sugars are preferred.
  • the resonance spectrum of a dialyzed and washed o-raffinose polymerized hemoglobin labelled with 4-amino- TEMPO was shown in Figure 9A.
  • ring-opened cross-linkers can be used to cross-link and polymerize hemoglobin to produce polymerized hemoglobin which is rich in oligomers.
  • the unreacted aldehyde, as described above, may be utilized to covalently attached to an amino- nitroxide, for example, 4-amino-TEMPO or 3-amino-PROXYL.
  • the ring-opened sulfate derivatives for example, the sulfated ⁇ -cyclodextran will be an effective cross-linker for two additional reasons: (1) the sulfate groups will mimic the activity of DPG in lowering the oxygen affinity of the cross-linked hemoglobin, thus improving oxygen transport properties, and (2) the sulfate groups will serve as affinity labels which will complex multiple (e.g.
  • the aldehyde groups on the cyclodextran will be brought to close proximity with the NH 2 groups within the DPG binding sites, thus promoting the covalent intra-subunit and inter-molecular cross-linking of hemoglobin resulting in an increased yield of hemoglobin oligomers.
  • the ring-opened cyclodextran polymerized and nitroxide- labelled hemoglobin will also have improved yield and composition as compared to ⁇ -raffinose and glutaldehyde polymerized hemoglobin.
  • Liposomes are particles which are formed from the aggregation of amphophilic molecules to form a bilayer structure in a hollow spherical shape with the polar sides facing an internal water compartment and external bulk water.
  • molecules form liposomes in aqueous solution like dipalmitoyl phosphatidylcholine.
  • Liposomes may be formulated with cholesterol for added stability and may include other materials such as neutral lipids, and surface modifiers such as positively or negatively charged compounds.
  • the preferred liposomes are small unilamellar-bilayered spherical shells.
  • a method for encapsulating hemoglobin in a liposome is also known (See Farmer et. al., United States Patent No. 4,911,921).
  • a number of approaches may be used to introduce the nitroxide-based oxygen detoxification function to a solution of liposome- encapsulated hemoglobin.
  • purified hemoglobin may also be coencapsulated with a membrane impermeable nitroxide such as TEMPO-choline chloride disclosed for a spin membrane immunoassay in Hsia et. al. United States Patent No. 4,235,792.
  • a membrane impermeable nitroxide such as TEMPO-choline chloride disclosed for a spin membrane immunoassay in Hsia et. al. United States Patent No. 4,235,792.
  • any purified hemoglobin may be encapsulated with a liposome comprised of nitroxide-labelled fatty acids (e.g.. 7-DOXYL-stearate, 12-DOXYL-stearic acid, and 16-DOXYL- stearate) , cholestane, an analogue of cholesterol (e.g.. 3- DOXYL-cholestane) , or phospholipid (e.g... 12-DOXYL-stearate- labelled phosphatidylcholine) .
  • the preparation of hemoglobin encapsulated in a liposome comprised of 3-DOXYL-cholestane labelled may be prepared by a method analogous to that described in Tabushi et.
  • the liposome encapsulated hemoglobin is then rotated and incubat ⁇ ed preferably at 37°C until all lipids are dispersed to form multilamellar vesicles.
  • the resulting solution containing multilamellar liposome encapsulated hemoglobin and free unencapsulated hemoglobin is then forced through a micro- fluidizer to form 0.2 micron liposomes according to the procedure of Cook et.al. (See U.S. Pat.4,533,254) .
  • the molar ratio of dipalmitoyl phosphatidylcoline: cholesterol: dipalmitidyl phosphatidic acid: 3-DOXYL-cholestane in the liposome is 0.5:0.4:0.02:0.07.
  • the resonance spectrum of the resulting 3-DOXYL-cholestane labelled liposome-encapsulated hemoglobin is shown in Figure 10A.
  • the nitroxide is intercalated into the liposome membrane and can be found at both the inner and outer surface of the lipid bilayer water interface.
  • Substituting the 3-DOXYL-cholestane with 16-DOXYL-stearic acid in the lipid composition shown in Figure 10A results in an electron resonance spectrum shown in Figure 10B.
  • the mobility of the nitroxide as reflected from the resonance spectrum is consistent with the interpretation that the DOXYL-moiety of the stearic acid is located predomi ⁇ nately in the hydrophobic interior of the lipid bilayer.
  • Figure IOC the resonance spectrum of the double nitroxide labelled liposome encapsulated hemoglobin is shown in Figure IOC.
  • the resonance spectrum of Figure IOC is a composite of Figures 10A and 10B because the nitroxides in this embodiment are located at both the membrane-water interface and its hydrophobic lipid bilayer interior.
  • this embodiment provides the oxygen detoxification function at both the lipid bilayer hydrophobic interior and the membrane-water interface thus providing the added benefit of an additional reserve of oxygen-detoxifica ⁇ tion capacity for the encapsulated hemoglobin.
  • a physiologically compatible solution of conjugated hemoglobin is produced by forming a conjugate of hemoglobin and a biocompatible macromolecule used as a plasma expander.
  • Plasma expanders such as dextran (Dx) , polyoxyethylene (POE) , hydroxylethyl starch (HES) , are used to increase the circulation half life of hemoglobin in the body.
  • Dx dextran
  • POE polyoxyethylene
  • HES hydroxylethyl starch
  • the hemoglobin molecules together with the bio ⁇ compatible macromolecule are collectively referred to as a hemoglobin conjugate.
  • hemoglobin may simply substitute the hemoglobin to be conjugated with a nitroxide-labelled hemoglobin such as TEMPO labelled DBBF-Hb.
  • a nitroxide-labelled hemoglobin such as TEMPO labelled DBBF-Hb.
  • This can be accomplished by substi- tuting hemoglobin or pyridoxylated hemoglobin with 3-malei- mido-PROXYL-DBBF-Hb or 4- (2-bromoacetamido) -TEMPO-DBBF-Hb in the preparation of conjugated hemoglobin.
  • 4-Amino-TEMPO labelled dextran conjugated hemoglobin is prepared in accord with the procedure described by Tarn et. al. (Proc. Natl. Acad. Sci., 73:2128 (1976)). Initially, an 8% hemoglobin solution in 0.15 M NaCl and 5 mM phosphate buffer, pH 7.4 is conjugated to periodate-oxidized dextran to form a Schiff-base intermediate. Twenty molar equivalents of 4-amino-TEMPO is added to hemoglobin to form the Schiff-base between the nitroxide and the remaining reactive aldehyde groups on the dextran. After a 30 minute of incubation at 4°C, a 50 molar equivalent of dimethylamine borane in water is added.
  • the solution is incubated for a further 2 hours at 4°C. Afterwards, the solution is dialyzed, reconstituted with Lactate Ringers buffer and sterile filtered with Filtron membrane filtration units (Filtron Technology Co.).
  • the electron spin resonance spectrum of the 4-amino-TEMPO labelled dextran-conjugated hemoglobin is a sharp asymmetric triplet reflecting a high degree of motional freedom (See Figure 11) .
  • the increased mobility of the TEMPO covalently attached to the Dextran is consistent with the nitroxide linked to a flexible polysaccharide dextran chain as compared to that of a tightly folded hemoglobin molecule (See Figures 3A and 3B) .
  • resonance spectrum in Figure 11 demon ⁇ strates that a novel nitroxide labelled dextran conjugated hemoglobin has been prepared.
  • nitroxides e.g.. TEMPOL
  • TEMPOL oxidized deoxyribonucleic acid
  • nitroxides can interact with peroxidases and pseudoperoxidases to achieve an activity mimicking that of catalase, the enzyme which converts hydrogen peroxide to oxygen.
  • the biological effects of nitroxide include contributing to protection against cytotox- icity of reactive oxygen species, apparently by reducing oxidative stress, for example, nitroxides protect against damage by ionizing radiation in vivo and in vi tro.
  • nitroxides when administered in vivo, display complex antioxidant enzyme-mimetic activities.
  • TEMPOL When injected intravenously, TEMPOL has been shown to have very short plasma half-life. Due to its molecular size and charge characteristics, it readily leaves the vascular space. In certain medical applications, other than those involving HBOC or HRCS, however, it may be desirable to have an antioxidant enzyme mimic which persists in the vascular space. This may be achieved by attaching a nitroxide compound to a macromolecule other than hemoglobin and which is biologically safe and has a desirable plasma half-life.
  • An example of such a desirable macromolecules is human serum albumin (HSA) .
  • Serum albumin is a plasma protein with multiple ligand- binding sites and is the transport protein for many ligands in the blood. Nitroxides can bind specifically to human serum albumin at a number of specific ligand binding sites, or non-specifically.
  • Nitroxide-labelled albumin may be used in vivo to provide protection against cellular ⁇ damage by reactive oxygen species.
  • Nitroxide-albumin may be used either alone or in combination with a low molecular weight nitroxide compound, e.g.. TEMPOL.
  • Nitroxide-labelled albumin is also available as an "improved" version of albumin (i.e.. improved by having antioxidant activity) with utility in any application where albumin is now conventionally used, including as a parenteral colloid solution, in biomaterials, in biocompatible surface coatings, etc.
  • the albumin may be obtained from plasma or may be produced by recombinant genetic means.
  • HSA may be used in a variety of forms, including monomers (normal plasma form) , homodimers, oligomers, and aggregates (microspheres) .
  • Specific labelling of the albumin with a nitroxide may be achieved at several binding sites, including bilirubin, FFA, indole, or Cu ++ binding site by using nitroxide compounds which have been activated in order to confer upon them binding specificity of the relevant site on the protein.
  • a preferred example is 2, 2, 6, 6-tetramethyl-l-oxyl-4-piperi- dylidene succinate (TOPS) nitroxide covalently bound to the primary bilirubin-binding site of HSA.
  • TOPS 2, 2, 6, 6-tetramethyl-l-oxyl-4-piperi- dylidene succinate
  • Non-specific label ⁇ ling of albumin may be achieved at approximately 50 accessi ⁇ ble amino groups.
  • nitroxides have been shown to have very short plasma half-life when injected intravenously. Due to the desire to have an antioxidant enzyme mimic with a long plasma half-life, a nitroxide compound may be attached to an immunoglobulin to provide long-lasting antioxidant enzyme mimic activity.
  • Immunoglobulins are a class of plasma proteins produced in the B-cells of the immune system and which are character ⁇ ized by two specific ligand binding sites (the antigen- binding sites) . Nitroxides have been used in the past as probes in research on hapten-binding specificity and affinity of immunoglobulins during the primary and secondary immune response.
  • nitroxide-labelling technology demon ⁇ strated above in the example of nitroxide-HBOC is readily applied to the production of nitroxide-labelled immunoglob ⁇ ulins.
  • Nitroxide-labelled immunoglobulins may be used in vivo to provide protection against cellular damage by reactive oxygen species.
  • Nitroxide-immunoglobulin may be used either alone or in combination with a low molecular weight nitroxide compound to provide extended antioxidant activity with an extended plasma half-life.
  • Nitroxide-labelled immunoglobulin may be prepared by specific labelling of the immunoglobulin itself or by covalently labelling at a hapten-binding site.
  • immuno ⁇ globulin fragments for example, (Fab) 2 produced by cleaving the immunoglobulin according to known techniques with non ⁇ specific-labelling, a preferred molar ratio of nitroxide:- immunoglobulin is up to 60:1.

Abstract

This invention relates to the technical field of compositions and processes to alleviate oxygen toxicity based on the addition of nitroxides to physiologically compatible macromolecules. In particular, hemoglobin-based red cell substitutes are described featuring stable nitroxide free radicals for use in cell-free hemoglobin solutions, encapsulated hemoglobin solutions, stabilized hemoglobin solutions, polymerized hemoglobin solutions, conjugated hemoglobin solutions, nitroxide-labelled albumin, and nitroxide-labelled immunoglobulin. The formulations described herein interact with free radicals, act as antioxidant enzyme-mimics, and alleviate oxidative stress and oxygen-related toxicity.

Description

COMPOSITION AND METHODS USING NITROXIDES TO AVOID OXYGEN TOXICITY
TECHNICAL FIELD This invention relates to the use of nitroxide compounds that are used with macromolecules, including hemoglobin, albumin, immunoglobulins and liposomes to alleviate the toxic effects of oxygen-related species in a living organism. In particular, this invention discloses compounds and methods featuring nitroxides associatedwithphysiologically compati¬ ble cell-free and encapsulated hemoglobin solutions for use as a red cell substitute and nitroxides associated with other physiologically compatible macromolecules for alleviation and prevention of damage and oxidative stress caused by free radicals.
BACKGROUND ART
Although the physiological mechanisms of oxygen metabo¬ lism have been known for many years, an understanding of the role played by oxidative stress in physiology and medicine is not well understood. The mechanism by which free radicals contribute to a variety of types of physiological damage has also been studied in connection with oxidative stress and its toxic effects. However, the development of methods and compounds to combat oxidative stress or toxicity associated with oxygen-related species has enjoyed limited success. The difficulties encountered in creating a blood substitute and are an acute example of the difficulty in preventing or alleviating oxygen toxicity.
Scientists and physicians have struggled for decades to produce a blood substitute that could be safely transfused into humans. Persistent blood shortages and the problems of incompatible blood types, cross-matching, and the communica¬ tion of disease have led to a broad-based effort by private industry, universities, and governments to discover a formulation that would allow a large volume of a blood substitute to be safely transfused without significant physiological side effects. At present, several companies are conducting clinical trials on experimental blood substi¬ tutes. However, unexpected adverse physiological reactions and the inherent complexity of the research and development process have impeded progress through the regulatory approval stage and have prevented the introduction of a clinically useful blood substitute.
A Research Advisory Committee of the United States Navy issued a report in August 1992 outlining the efforts by several groups to produce a blood substitute, assessing the status of those efforts, and generally describing the toxicity problems encountered. The Naval Research Advisory Committee Report reflects the current consensus in the scientific community that even though the existing blood substitute products, often termed "hemoglobin-based oxygen carriers" (HBOC) , have demonstrated efficacy in oxygen transport, certain toxicity issues are unresolved. The adverse transfusion reactions that have been observed in clinical studies of existing hemoglobin-based oxygen carriers (HBOC) include systemic hypertension and vasoconstriction. These adverse reactions have forced a number of pharmaceuti¬ cal companies to abandon their clinical trials or to proceed at low dosage levels.
The toxicity problem in the existing hemoglobin-based blood substitutes has been given a high priority by the United States Government. The Naval Research Committee recommendation has been implemented by the National Institute of Health in the form of a Request For Proposal (PA-93-23) on the subject of "Hemoglobin-Based Oxygen Carriers: Mechanism of Toxicity. " Therefore, the medical and scientific communi¬ ty suffers from an acute and pressing need for a blood substitute that may be infused without the side effects observed with the existing hemoglobin-based oxygen carriers.
The red blood cells are the major component of blood and contain the body's oxygen transport system. It has long been recognized that the most important characteristic of a blood substitute is the ability to carry oxygen. The red blood cells are able to carry oxygen because the primary component of the red cells is hemoglobin, which functions as the oxygen carrier. Most of the products undergoing clinical testing as blood substitutes contain hemoglobin that has been separated from the red blood cell membranes and the remaining constitu¬ ents of the red blood cells and has been purified to remove essentially all contaminants. However, when hemoglobin is removed from the red cells and placed in solution in its native form, it is unstable and rapidly dissociates into its constituent subunits. For this reason, the hemoglobin used in a hemoglobin-based oxygen carrier (HBOC) must be stabi¬ lized to prevent dissociation in solution. Substantial expenditures in scientific labor and capital were necessary to develop hemoglobin-based products that are stable in solution, and which are stabilized in such a way that the oxygen transport function is not impaired. The ability of the existing hemoglobin-based oxygen carriers to transport oxygen has been well established (See United States Patent Nos. 3,925,344; 4,001,200; 4,001,401; 4,053,590; 4,061,736 4,136,093; 4,301,144; 4,336,248; 4,376,095; 4,377,512 4,401,652; 4,473,494; 4,473,496; 4,600,531; 4,584,130 4,857,636; 4,826,811; 4,911,929 and 5,061,688).
In the body, hemoglobin in the red cells binds oxygen molecules as the blood passes through the lungs and delivers the oxygen molecules throughout the body to meet the demands of the body's normal metabolic function. However, the atmospheric oxygen that most living beings must breathe to survive is a scientific and medical paradox. On the one hand, almost all living organisms require oxygen for life. On the other hand, a variety of toxic oxygen-related chemical species are produced during normal oxygen metabolism.
With respect to oxidative stress resulting from the transportation of oxygen by hemoglobin, it is known that in the process of transporting oxygen, the hemoglobin (Hb) molecule can itself be oxidized by the oxygen (02) molecule it is carrying. This auto-oxidation reaction produces two undesirable products: met-hemoglobin (met-Hb) and the superoxide anion ( •07) • The chemical reaction may be written as follows:
Hb + 4 02 * met-Hb + 4 -0^ [1]
The superoxide anion (•0 ) is an oxygen molecule that carries an additional electron and a negative charge. The superoxide anion is highly reactive and toxic. In the case of oxygen transport by hemoglobin, potentially damaging oxidative stress originates with the superoxide anion being generated by the auto-oxidation of hemoglobin and results from the subsequent conversion of the superoxide anion to toxic hydrogen peroxide in the presence of the enzyme superoxide dismutase (SOD) by the following reaction:
2 -0 + 2H+ > 2 02 + H202 [2]
The presence of the superoxide anion and hydrogen peroxide in the red blood cells is believed to be the major source of oxidative stress to the red cells.
Apart from oxygen transport by the hemoglobin continued therein, a less recognized characteristic of the red cells is that they contain a specific set of enzymes which are capable of detoxifying oxygen-related chemical species produced as by-products of oxygen metabolism. Without the protection of these specific enzyme systems, autoxidation of hemoglobin would lead to deterioration and destruction of the red cells. In the body, however, the reserve capacity of the enzyme systems in the red cells protects the body from oxygen toxicity by converting the superoxide anion generated during normal metabolism to non-toxic species and thereby controls the level of oxidative stress. However, if this enzyme system breaks down, the integrity of the red cells will be damaged. A lesion of the gene that produces one of the enzymes in the protective system in the red blood cells will cause an observable pathological condition. For example, glucose-6-phosphate dehydrogenase deficiency, a genetic disorder of red cells, is responsible for hydrogen peroxide induced hemolytic anemia. This disorder is due to the inability of the affected cells to maintain NAD(P)H levels sufficient for the reduction of oxidized glutathione result¬ ing in inadequate detoxification of hydrogen peroxide through glutathione peroxidase (P. Hochstein, Free Radical Biology & Medicine, 5:387 (1988)). The protective enzyme system of the red blood cells converts the toxic superoxide anion molecule to a non-toxic form in a two-step chemical pathway. The first step of the pathway is the conversion of the superoxide anion to hydrogen peroxide by the enzyme superoxide dismutase (SOD) (See Equation [2] ) . Because hydrogen peroxide is also toxic to cells, the red cells contain another enzyme, catalase, which converts hydrogen peroxide to water as the second step of the pathway (See Equation [3] ) .
2 H202 * 2 H20 + 02 [3]
Red cells are also capable of detoxifying hydrogen peroxide and other toxic organoperoxides using the enzyme glutathione peroxidase which reacts with glutathione to convert hydrogen peroxide and organoperoxides to water. Red cells also contain an enzyme to prevent the build up of the met-hemoglo¬ bin produced by the auto-oxidation of hemoglobin. The enzyme met-hemoglobin reductase converts met-hemoglobin back to the native form of hemoglobin. Therefore, in the body, the toxic effects of the auto-oxidation of hemoglobin are prevented by specific enzyme-based reaction pathways that eliminate the unwanted by-products of oxygen metabolism.
The enzymatic oxygen detoxification functions of superox¬ ide dismutase, catalase, and glutathione peroxidase that protect red blood cells from oxygen toxicity during normal oxygen transport do not exist in the hemoglobin-based oxygen carriers (HBOC) developed to date. Without the oxygen detoxification function, the safety of the existing HBOC solutions will suffer due to the presence of toxic oxygen- related species.
The principle method by which the existing HBOC solutions are manufactured is through the removal of hemoglobin from the red cells and subsequent purification to remove all non- hemoglobin proteins and other impurities that may cause an adverse reaction during transfusion (See United States Patent Nos. 4,780,210; 4,831,012; and 4,925,574). The substantial destruction or removal of the oxygen detoxification enzyme systems is an unavoidable result of the existing isolation and purification processes that yield the purified hemoglobin used in most HBOCs. Alternatively, instead of isolating and purifying hemoglobin from red cells, pure hemoglobin has been produced using recombinant techniques. However, recombinant human hemoglobin is also highly purified and does not contain the oxygen detoxification systems found in the red cells. Thus, the development of sophisticated techniques to create a highly purified hemoglobin solution is a mixed blessing because the purification processes remove the detrimental impurities and the beneficial oxygen detoxification enzymes normally present in the red cells and ultimately contributes to oxygen-related toxicity.
One of the observed toxic side effects of the existing HBOCs is vasoconstriction or hypertension. It is well known that the enzyme superoxide dismutase (SOD) i vitro will rapidly scavenge the superoxide anion and prolong the vasorelaxant effect of nitric oxide (NO) . Nitric oxide is a molecule that has recently been discovered to be the sub¬ stance previously known only as the "endothelium-derived relaxing factor" (EDRF) . The prolongation of the vasorelax¬ ant effect of nitric oxide by SOD has been ascribed to the ability of SOD to prevent the reaction between the superoxide anion and nitric oxide. (M.E. Murphy et. al., Proc. Natl. Acad. Sci. USA 88:10860 (1991); Ignarro et.al. J. Pharmacol. Exp. Ther. 244: 81 (1988); Rubanyi Am. J. Physiol. 250: H822 (1986); Gryglewski et.al. Nature 320: 454 (1986)).
However, in vivo, the inactivation of EDRF by the superoxide anion has not been observed and is generally not thought to be likely. Nevertheless, certain pathophysiologi- cal conditions that impair SOD activity could result in toxic effects caused by the superoxide anion (Ignarro L.J. Annu. Rev. Pharmacol. Toxicol. 30:535 (1990)). The hypertensive effect observed in preclinical animal studies of the existing HBOC solutions suggests that the concentration of superoxide anion in large volume transfusions of the existing HBOCs is the cause for the destruction of EDRF and the observed vasoconstriction and systemic hypertension.
It is, therefore, important to delineate the hypertensive effect resulting from the reaction of the superoxide anion with nitric oxide (NO) from that resulting from extravasation and the binding of NO by hemoglobin. Upon transfusion of an HBOC, the hemoglobin can also depress the vasorelaxant action of nitric oxide by reacting with nitric oxide to yield the corresponding nitrosyl-heme (NO-heme) adduct. In particular, deoxy-hemoglobin is known to bind nitric oxide with an affinity which is several orders of magnitude higher than that of carbon monoxide. These hemoglobin-NO interactions have been used to assay for nitric oxide and to study the biological activity of nitric oxide. For example, the antagonism of the vasorelaxant effect of nitric oxide by hemoglobin appears to be dependent on the cell membrane permeability of hemoglobin. In intact platelets, hemoglobin did not reverse the effect of L-arginine which is the precursor of nitric oxide. In contrast, in the cytosol of lysed platelets, hemoglobin is the most effective inhibitor of L-arginine induced cyclic-GMP formation mediated by nitric oxide. These experiments demonstrated that the hemoglobin did not penetrate the platelet membrane effectively. (Radomski et.al. Br. J. Pharmacol. 101:325 (1990)). Therefore, one of the desired characteristics of the HBOCs is to eliminate the interaction of nitric oxide with hemoglobin. Hemoglobin is also known to antagonize both endothelium- dependent vascular relaxation ( Martin W. et. al. J. Pharma¬ col. Exp. Ther. 232: 708 (1985)) as well as NO-elicited vascular smooth muscle relaxation (Grueter CA. et. al. J. Cyclic. Nucleotide Res. 5:211 (1979)) . Attempts have been made to limit the extravasation and hypertensive effect of hemoglobin by chemically stabilizing, polymerizing, encapsu¬ lating, or conjugating the hemoglobin in the HBOCs to prolong the circulation time. Therefore, although the current HBOCs are relatively membrane impermeable and able to transport oxygen, the HBOC solutions do not have the capability of preventing the reaction between superoxide anion and nitric oxide when transfused.
An ideal solution to the toxicity problems of the existing blood substitutes would be a hemoglobin-based formulation that combines the oxygen-transport function of the existing HBOCs with the oxygen detoxification function of the red cells. However, a simple addition of the enzyme superoxide dismutase (SOD) into an existing HBOC solution would not be desirable because, by reducing the concentration of superoxide anion, the reaction whereby hemoglobin is oxidized to met-hemoglobin would be encouraged, leading to an undesirable build-up of met-hemoglobin (See Equation [1] ) . Also, it is not desirable to encourage the conversion of the superoxide anion to hydrogen peroxide in a hemoglobin solution because the hydrogen peroxide is toxic and reactive and will decompose to toxic hydroxyl radicals or form other toxic organoperoxides during storage.
This invention contemplates the use of stable nitroxide free radicals, hereafter referred to as "nitroxide(s) ", to provide the oxygen detoxification function of the red cells to hemoglobin-based blood substitutes and to alleviate oxidative stress to avoid biological damage associated with free radical toxicity, including inflammation, post-ischemic reperfusion injury, ionizing radiation, and the aging process. Nitroxides are stable free radicals that are shown to have antioxidant catalytic activities which mimic those of superoxide dismutase (SOD) , and which when existing in vivo. can interact with other substances to perform catalase-mimic activity. In the past, nitroxides have been used in electron spin resonance spectroscopy as "spin labels" for studying conformational and motional characteristics of biomacromole- cules. Nitroxides have also been used to detect reactive free radical intermediates because their chemical structure provides a stable unpaired electron with well defined hyperfine interactions. In addition, nitroxides have been observed to act as enzyme mimics; certain low molecular weight nitroxides have been identified to mimic the activity of superoxide dismutase (SOD). (A. Samuni et. al. J. Biol. Chem. 263:17921 (1988)) and catalase (R.J. Mehlhorn et. al. , Free Rad. Res. Comm. , 17:157 (1992)). Numerous studies also show that nitroxides that are permeable to cell membranes are capable of short-term protection of mammalian cells against cytotoxicity from superoxide anion generated by hypoxan- thine/xanthine oxidase and from hydrogen peroxide exposure. With regard to safety in vivo, relatively high levels of nitroxide are expected to be well tolerated as nitroxides are known to be relatively safe: for example, the maximum tolerated intraperitoneal dose of TEMPO in mice is 275 mg/kg and the LD50 is 341 mg/kg. Further, a macromolecule-bound nitroxide will be safer than a free nitroxide. The utility of nitroxide-labelled macromolecule as an antioxidant enzyme mimic, therefore, lies in the possibility of achieving high nitroxide levels (and hence activity) with acceptable safety.
Most of the nitroxides studied to date in living organ¬ isms have been relatively low molecular weight compounds which can easily permeate across cell membranes into body tissues. The nitroxides used as enzyme mimics, pursuant to this invention, are associated with biological and synthetic macromolecules which may be infused and may remain confined to the vascular compartment. In the preferred embodiments of this invention, nitroxides are covalently attached to macromolecules to alleviate free radical toxicity while confining the nitroxide to the location, i.e. , the vascular compartment, where their utility in reacting with free radicals is optimized.
A variety of techniques have been described to covalently attach a nitroxide to biomacromolecules, including hemoglo¬ bin, albumin, immunoglobulins, and liposomes. See e.g. , McConnell et. al. , Quart. Rev. Biophys. 3:p.91 (1970); Hamilton et. al., "Structural Chemistry and Molecular Biology" A. Rich et. al., eds. W.H. Freeman, San Francisco, p.115 (1968); Griffith et. al. , Ace. Chem. Res. 2:p.l7 (1969); Smith I.C.P. "Biological Applications of Electron Spin Resonance Spectroscopy" Swartz, H.M. et. al., eds., Wiley/Interscience, New York p.483 (1972) . Although selected nitroxides have been covalently bound to hemoglobin molecules for the purpose of studying cooperative oxygen binding mechanisms of hemoglobin, nitroxides have not been used in connection with hemoglobin that is specially formulated for use with blood substitutes. Experimental results are presented below to demonstrate that nitroxides may be attached to stabilized, polymerized, conjugated and encapsu¬ lated hemoglobin for use as a blood substitute because the nitroxide reacts with free radicals. The interaction of nitroxide-labelled hemoglobin with free radicals also suggests that other biologically compatible macromolecules with a substantial plasma half-life may be labelled with nitroxides to advantageously provide resistance to or protection from oxidative stress or toxicity caused by free radical chemical species.
As noted above, it is known that nitroxides can be chemically bound to biological macromolecules, including hemoglobin, serum albumin, immunoglobulins, and liposomes. However, this work has generally used nitroxides simply as molecular probes for biophysical research; nitroxide-labeled macromolecules have not been specially formulated for use as therapeutic substances. With respect to the macromolecules described here, two techniques for binding the nitroxides to a macromolecule, often known as "labelling strategies" are possible. The significance of specific labelling lies in the micro-environ¬ ment in which the nitroxide is bound to the macromolecule and the nitroxide's resulting catalytic activity. Specific labelling at a particular ligand binding site or sites will yield a homogeneous product with a more consistent binding site micro-environment and thus a more reliable compound in terms of the catalytic specificity and activity of the nitroxide.
Based on the experimental results presented here involv¬ ing the infusion of nitroxide-labelled HBOC, the reaction of small and large molecular weight nitroxides with free radicals has been observed in vitro and in vivo in the vascular compartment. Based on these studies, the reaction mechanism whereby nitroxide-labelled HBOC participates in the oxidation/reduction reaction of free radicals demonstrates the capability to formulate novel HBOC compounds and other nitroxide-labelled macromolecules to detoxify free radicals.
DISCLOSURE OF INVENTION This invention discloses compositions and methods using stable nitroxides in connection with biological macromole¬ cules and, in particular, with hemoglobin-containing solu¬ tions. In particular embodiments, stable nitroxides are used with hemoglobin-containing solutions to create several formulations for a blood substitute that will possess the oxygen detoxification function of the red cells. These formulations may be described herein as hemoglobin-based red cell substitutes (HRCs) because the oxygen transport capabil¬ ity of the hemoglobin-based oxygen carriers (HBOC) is enhanced by providing the oxygen detoxification function of the body's red cells. The nitroxide-labelled albumin and nitroxide-labelled immunoglobulins also provide oxygen detoxification by providing a nitroxide covalently attached to a macromolecule possessing a variety of characterized ligand binding sites that is both stable and non-toxic in vivo, and which has a substantial plasma half-life.
In addition, this invention describes nitroxides that are covalently attached to the inner surface of a container or are attached to an insoluble matrix housed in a filter to be used with an existing HBOC to scavenge toxic oxygen-related compounds before infusion into a patient. The HRCS formula¬ tions described herein will alleviate the oxidative stress originating from the generation of the superoxide anion in the existing HBOC solutions, and upon transfusion, will diminish the destruction of nitric oxide, the endothelium- derived relaxing factor (EDRF) . If the destruction of EDRF is prevented, the problem of vasoconstriction and systemic hypertension that are observed when the existing HBOC solutions are infused into a patient will be substantially alleviated.
The HRCS formulations and nitroxide-labelled macromole¬ cules described below retard the formation of toxic oxygen- related species by causing a nitroxide to function as a "superoxide oxidase," an enzyme-like reaction not known to occur in the red cells. In these HRCS formulations, the nitroxide prevents the accumulation of the undesirable superoxide anion generated from the auto-oxidation of hemoglobin (See Equation [1]) . The nitroxide-labelled albumin and immunoglobulins similarly function as antioxidant enzyme mimics whose function remains localized in the vascular and interstitial compartments.
In the "superoxide oxidase" reaction, the superoxide anion is oxidized back into molecular oxygen without proceed¬ ing to the formation of hydrogen peroxide. This is accom¬ plished in part by creating a storage condition wherein the concentration of nitroxide greatly exceeds that of oxygen. Used in the manner disclosed herein, the nitroxide prevents the cascade of undesirable oxidative reactions that begin with the formation of the superoxide anion. Furthermore, the physiologically compatible HRCS solutions described here will offer advantages over the existing HBOC solutions because the nitroxide will mimic the enzymatic activity of superoxide dismutase and catalase after the formulations described herein are infused into a patient.
Preferred compositions using nitroxide in connection with a physiologically compatible hemoglobin solutions include: 1) nitroxide attached to a storage container or covalently attached to an insoluble matrix used as a filter, 2) nit¬ roxide covalently linked to hemoglobin that is stabilized by chemical or recombinant cross-linking, 3) nitroxide covalent¬ ly linked to polymerized hemoglobin, in particular, in 2, 4, and 8 molar equivalents of nitroxide, 4) nitroxide co- encapsulated with hemoglobin inside a liposome or intercalat¬ ed into a liposome membrane, (5) nitroxide covalently bound to conjugated hemoglobin, (6) nitroxide covalently bound to albumin, and (7) nitroxide covalently bound to immunoglob¬ ulins.
Also, HRCS based on the co-encapsulation of a membrane- impermeable nitroxide with hemoglobin is disclosed. The methods of preparing the above formulations are described as are methods for producing nitroxide-containing filters and containers for the storage and detoxification of an existing HBOC.
Preferred compositions using nitroxide in connection with human serum albumin or recombinant albumin include:
1) non-specific labelling of albumin with nitroxide (e.g. , 4- (2-bromoacetamido) -TEMPO at high nitroxide to albumin ratios; and
2) specific labelling of albumin at specific ligand binding sites .
Preferred compositions using nitroxide in connection with immunoglobulins include a nitroxide labelled hapten or antigen bound to an immunoglobulin specific for the hapten or antigen.
BRIEF DESCRIPTION OF DRAWINGS
Figures 1A and IB show the electron spin resonance spectra of 4-amino-TEMPO labelled o-raffinose polymerized hemoglobin recorded on (A) day 1 and (B) day 30 (TEMPO: 2,2,6,6 tetramethylpiperidine-1-oxyl) . Figure 1C is the spectra of the sample in Figure 1A diluted with equal volume of unlabelled hemoglobin recorded on day 1. Figure ID is the sample in Figure 1C recorded on day 30.
Figures 2A and 2B are, respectively, the electron spin resonance spectra demonstrating covalent attachment of 4- (2- bromoacetamido) -TEMPO to ω-aminohexyl-agarose and 4-amino- TEMPO to 1,4-bis(2:3-Epoxypropoxy) butane-activated agarose.
Figures 3A and 3B, respectively, are electron spin resonance spectra demonstrating successful covalent attach¬ ment of 4- (2-Bromoacetamido) -TEMPO and 3-maleimido-PROXYL to 3,5-bis-bromosilicyl-bisfumarate (DBBF) cross-linked or diaspirin cross-linked human hemoglobin.
Figure 4A is an ESR spectra of 4- (2-bromoacetamido) - TEMPO. Figure 4B is an ESR spectra of 4- (2-bromoacetamido) - TEMPO-labelled HBOC. Figure 4C is an ESR spectra of 15ND17 TEMPOL in Lactated Ringer's solution recorded at room temperature. Figure 5 is an ESR spectra of 4- (2-bromoacetamido) -TEMPO- labelled HBOC with different molar ratios of nitroxides to Hb; Fig. 5A 2:1, Fig. 5B 4:1 and Fig. 5C 8:1. The instrument sensitivity were decreased proportionately from Fig. 5A to Fig. 5B to Fig. 5C to record the spectra so that the center peak (Mo) would be shown to have similar peak height.
Figure 6 is an ESR spectrum of a mixture of 4- (2-bromo¬ acetamido) -TEMPO labelled HBOC and 15ND17 -TEMPOL wherein the center peak (see down arrow) of the former and the high field peak (see up-arrow) of the latter were adjusted to similar intensity. This is a superimposition of ESR spectrum from Fig. 4B and Fig. 4C.
Figure 7 is a plasma half-life of 4- (2-bromoacetamido) - TEMPO-labelled HBOC in mouse. Fig. 7A is the ESR spectrum of the nitroxide signal recorded from the mouse tail approxi¬ mately 10 minutes after i.v. infusion of 0.5 ml of the sample shown in Fig. 6. Fig. 7B is the time dependent (scan time 30 minutes) decrease in the center peak (Mo) signal intensity of Fig. 7A recorded at 10 times of the instrument sensitivity. Fig. 7C is a continuation of Fig. 7B at the end of its scan.
Figure 8 is a plasma half-life of a mixture of 4- (2- bromoacetamido) -TEMPO-labelled HBOC (8g/dl of Hb and 8:1 TEMPO to Hb) and 15ND17 TEMPOL (0.5 ml in a 32 g. mouse) recorded from the mouse tail with a cannula for immediate recording of the infused nitroxides. The ESR spectrum of the sample prior to injection is shown in Fig. 6. Fig. 8A is a series of 5 ESR spectrum recorded at 0.5 minute intervals, the magnetic field strength was increased by 2 Gauss in between each scan to display the decrease in signal intensity as a function of time. Fig. 8B is the continuation from Fig. 8A of repeated recording of a series of 6 ESR spectrum at the same time intervals except that the magnetic field strength was decreased by 2 Gauss in between each scan.
Figures 9A and 9B, respectively, are electron spin resonance spectra demonstrating 4-amino-TEMPO labelled and o- raffinose cross-linked and polymerized human hemoglobin and 3-maleimido-PROXYL labelled DBBF-hemoglobin polymerized with glutaldehyde.
Figures 10A, 10B, and IOC respectively, are electron spin resonance spectra of liposome encapsulated human hemoglobin containing (A) 3-DOXYL-cholestane (B) 16-DOXYL-stearic acid and (C) both 3-DOXYL-cholestane and 16-DOXYL-stearate.
Figure 11 is the electron spin resonance spectrum of nitroxide-labelled hemoglobin labelled with 4-amino-TEMPO and conjugated with dextran.
Figure 12 is an embodiment of a filter cartridge that contains a solid matrix to which a nitroxide is bound and through which a hemoglobin-containing solution may be passed.
INDUSTRIAL APPLICABILITY The term "hemoglobin" is used generally herein to describe oxy-, carboxy-, carbonmonoxy-, and deoxy-hemoglobin except as otherwise noted by the context of the description. The hemoglobin used with this invention may be human, recombinant or animal in origin and is obtained and purified by known techniques. The hemoglobin may be covalently bound to pyridoxal groups of pyridoxal-5' -phosphate or ring opened adenosine triphosphate (o-ATP) by reaction with the aldehyde groups and cross-linked derivatives of hemoglobin. The cross-linked derivatives may include polyfunctional, hetero- bifunctional and homobifunctional cross-linking regents such as dialdehyde, polyaldehyde, diepoxide, polyepoxide, activat¬ ed polycarboxyl and dicarboxyl groups, for example, 3,5-bis- bromosilicyl-bisfumarate, and TEMPO succinate or TOPS See (U.S. Patent No. 4,240,797) cyclodextrans and their anionic (e.g.. sulfate) cross-linked hemoglobin as well as polymer¬ ized hemoglobin. All hemoglobin solutions described herein for use with this invention are physiologically compatible. The hemoglobin solutions are cell-free to remove pyrogens, endotoxins, and other contaminants.
The term "nitroxide" is used herein to describe stable nitroxide free radicals, their precursors, and their deriva¬ tives thereof including the corresponding hydroxylamine derivative where the oxygen atoms are replaced with a hydroxyl group and exist in hydrogen halide form. For the purposes of this invention, the chloride salt form of the hydroxylamine derivatives are preferred.
In the nitroxides described here, the unpaired electron of a nitroxide is stable in part because the nitrogen nucleus is attached to two carbon atoms which are substituted with strong electron donors. With the partial negative charge on the oxygen of the N-0 bond, the two adjacent carbon atoms together localize the unpaired electron on the nitrogen nucleus.
Nitroxides may have either a heterocyclic or linear structure. The fundamental criterion is a stable free radical. Structurally, nitroxides of the following formula are preferred where Rx - R4 are electron donors and A is the remaining members of a heterocyclic ring.
Figure imgf000024_0001
In these heterocyclic structures, "A" represents the remaining carbon atoms of a 5-membered (pyrrolidinyl or PROXYL with one double bond, i.e.. pyrroline) or a 6-membered (piperidinyl or TEMPO) heterocyclic structure and in which one carbon atoms may be substituted with an oxygen atom (oxazolinyl or DOXYL) and certain hydrogen atoms may be substituted with up to two bromine atoms. In such heterocy¬ clic structures, stable isotopes may be utilized (e.g., N15, deuterium) . Substitution at the carbons should be such that the unpaired electron is maintained substantially in a 7ip orbital configuration. Rx through R4 are alkyls (straight and branched chain) or aryl groups but are preferred to be methyl or ethyl groups. The substituent groups on the alpha carbons in any nitroxide should be strong electron donors to enhance stability, thus methyl (CH3) groups or ethyl (C2H5) groups are preferred although other longer carbon chain species could be used. In practice, stearic considerations may limit the scope of the nitroxide compounds that are practical and economical. The preferred nitroxides used with this invention include nitroxides having the following structure:
Figure imgf000025_0001
ooxri
(4.4-Oim«thyl-3-
OM.olinyto.y-)
(4.4- Dimelhylou. otidint ■ (2,2
N-oiyl)
Figure imgf000025_0002
As is apparent from the above, most suitable nitroxide compounds may be represented basically by the structural formula
R N-0 assuming that the R group is selected from among the configu¬ rations which preserve the stability of the free radical. The nitroxides which can be employed in this invention are structurally diverse because the requisite property of the nitroxides is their ability to influence the course of the superoxide anion cascade in HRCS by mimicking the superoxide oxidase, superoxide dismutase, and catalase activities without substantially being consumed in the process. Although a wide variety of nitroxides may be used with this invention, the nitroxide should be physiologically acceptable at a minimum concentration required to alleviate oxygen toxicity in the HRCS. In assessing an operative species, it is noteworthy that the relatively low toxicity of nitroxides has encouraged their development as contrasting agent in NMR imaging (See U.S. Patent Nos. 4,834,964; 4,863,717; 5,104,641) .
A number of methods for isolating and purifying hemoglo¬ bin solutions such that they are physiologically compatible are known to those skilled in the art. Typically, purified hemoglobin compositions contain at least 99% hemoglobin by weight of total protein, a total phospholipid content of less than about 3ug/ml, less than lug/ml of either phosphatidyl- serine or phosphatidylethanolamine and an inactive heme pigment of less than 6%. The purified hemoglobin solutions which are useful in this invention can be prepared using a variety of conventional techniques, including but are not limited to, those disclosed in Cheung et. al., Anal Biochem 137:481-484 (1984), De Venuto et. al. , J. Lab. Clin. fled. 89:509-516 (1977), and Lee, et. al. , Vith International Symposium on Blood Substitutes, San Diego, CA Mar. 17-20 Abstract H51 (1993) .
The purified hemoglobin solutions used in this invention should be essentially free of oxygen. Hemoglobin in solution may be deoxygenated by admixture with a chemical reducing agent which causes the hemoglobin to release oxygen and to be maintained in a substantially deoxygenated state. A pre¬ ferred method for deoxygenating a hemoglobin solution is performed by exposing a hemoglobin solution to an inert, essentially oxygen-free gas, such as nitrogen or carbon monoxide to cause removal of bound oxygen from the hemoglobin and conversion of the hemoglobin in solution to a form such as deoxy-hemoglobin or carbonmonoxy-hemoglobin that lacks oxygen. Alternatively, hemoglobin may be exposed to a vacuum or gas through a membrane that is permeable to oxygen yet impermeable to hemoglobin. For example, a hemoglobin solution may be passed through a diffusion cell having a membrane wall along which hemoglobin flows and through which oxygen is capable of passing, but hemoglobin is not. Inert gas is circulated along the side of the membrane wall opposite the hemoglobin solution causing the removal of oxygen and the conversion of the hemoglobin in solution to the deoxygenated state. Preferably, the deoxy-hemoglobin is maintained in an essentially oxygen-free environment during nitroxide labelling, cross-linking, polymerization, or conjugation.
After removal of any bound oxygen, a nitroxide is covalently attached to the hemoglobin. Normally at least one, and preferably more than one, nitroxide will be cova¬ lently attached to a single hemoglobin molecule. The nitroxide may be covalently attached to the hemoglobin at any of several sites on the hemoglobin molecule including:
(a) at one or more of the free sulfhydro (-SH) groups, for example, at the 0 - 93 site;
(b) at any reactive amino (-NH2) groups, for example, in the DPG site at Val-1 of the /S-chain and/or lysine- 82 of the jS-chain and/or lysine-99 of the α-chain;
(c) at any non-specific surface amino (-NH2) or carboxyl (-COOH) group;
A nitroxide may also be bound to any residual aldehyde, epoxy, or activated carboxyl groups of a divalent- or a multivalent-cross-linker involved in the cross-linking and polymerization of hemoglobin or at any residual reactive groups on an agent such as dextran (Dx) or hydroxylethyl- starch (HES) or polyoxyethylene (POE) used to conjugate hemoglobin.
As described in Equation [1] , above, during the storage period, the hemoglobin in an HBOC solution is slowly auto- oxidized by oxygen to form met-hemoglobin and the superoxide anion. However, during the storage of the HRCS that are the subject of this invention, the superoxide anion thus formed will reduce the nitroxide to a hydroxylamine derivative, and the superoxide anion will be oxidized to form molecular oxygen by the following reaction.
H+ + R N-^0 R N-OH + t4]
The conversion of superoxide anion to molecular oxygen described in Equation [4] prevents the accumulation of superoxide anion and the subsequent formation of hydrogen peroxide. This activity, described herein as a "superoxide oxidase" activity, will be most effective when the initial oxygen content in the composition is kept to a minimum, the composition is stored in an essentially oxygen free environ¬ ment and the nitroxide concentration is sufficient to prevent the formation of superoxide anion and hydrogen peroxide. Therefore, storage of the HRCS in an essentially oxygen-free container is preferred.
Container systems that permit a solution to be stored in an oxygen free environment are well known because many non- hemoglobin based intravenous solutions are sensitive to oxygen. For example, a glass container that is purged of oxygen during the filling and sealing process may be used. Also, flexible plastic containers are available that may be enclosed in an overwrap to seal against oxygen. Basically, any container that prevents oxygen from interacting with hemoglobin in solution may be used. To demonstrate the "superoxide oxidase" activity of a nitroxide, samples of nitroxide-labelled hemoglobin in solution are kept in an accelerated oxidative storage condition and the redox state of the nitroxide is studied over time by electron spin resonance spectroscopy. For example, an o-raffinose polymerized hemoglobin solution that has been labelled with 4-amino-TEMPO is stored in its oxygenated state in a sealed glass container (Figure 1A) . In such a state, the rate of superoxide anion and met-hemoglobin formation in solution is sufficiently rapid that the conver¬ sion of the nitroxide to its hydroxylamine derivatives may be conveniently monitored (See Equation [4] and compare Figures 1A and IB) . Equation 4 represents that the conversion of nitroxide to its diamagnetic hydroxyl derivative is coupled to the conversion of the superoxide anion back to molecular oxygen. The experimental evidence in support of such a conversion is shown in Figures 1A and IB. The electron spin resonance spectrum of TEMPO covalently attached to the hemoglobin (Figure 1A) was converted to its diamagnetic derivatives which result in the complete disappearance of the resonance peaks after storage of the sample for 30 days at 4°C (Figure IB) . The nitroxide is considered to have per¬ formed a "superoxide oxidase"-like activity when it is converted to its hydroxylamine derivative in the presence of hemoglobin.
The "superoxide dismutase" activity of a nitroxide in an HBOC solution is demonstrated by showing the reconversion of the hydroxylamine derivative back to a nitroxide (See Equation [5] together with Equation [4] ) . Knowing that under the experimental conditions described in Figures 1A and IB the nitroxide is fully converted to hydroxylamine (See Equation [4] ) , the nitroxide may be regenerated by simply providing more superoxide anion as shown in Equation 5. To demonstrate this reaction mechanism, the relative concentra¬ tion of hemoglobin (and thus superoxide anion) to the nitroxide is increased by diluting the sample in Figure 1A with an equal volume of unlabelled hemoglobin. A comparison of Figures 1A and 1C shows an approximate 50% reduction of the signal intensity of the nitroxide due to the dilution effect. On the other hand, after 30 days of cold storage at 4°C, the nitroxide was partially regenerated (See Figure ID) as predicted by Equation [5] . This observation is consistent with the reconversion of the hydroxylamine derivative to nitroxide coupled with the formation of hydrogen peroxide from superoxide anion.
Figure imgf000031_0001
Summing equations [4] and [5] results in :
2 - 0, + 2H* > 02 + H2 20W2. which demonstrates that the nitroxide acts as a low molecular weight, metal-free, SOD mimic in "HBOC" solutions. The detection of electron spin resonance spectrum of the nitrox¬ ide (in Figure ID) is consistent with the reaction of superoxide anion with the hydroxylamine (R N-OH) resulting in the formation of nitroxide (R N^-O) and hydrogen peroxide
(H202) . Recently, oxoammonium cation has been proposed to be involved as one intermediate in the nitroxide catalyzed dismutation of superoxide. (Krishna et al., Proc. Nat. Acad. Sci. USA 89. 5537-5541 (1992)).
The number of nitroxide molecules per hemoglobin molecule may be in the range of approximately 1-40 and for specific labelling is most preferably about 2. However, the nitr¬ oxide-hemoglobin ratio should be kept to a minimum due to pharmacokinetic, toxicological and immunological consider¬ ations. For example, a nitroxide such as 3-maleimido-PROXYL is covalently bound to hemoglobin in solution by first preparing a lOOmM solution of the nitroxide in ethanol as the carrier solvent. Two(2) molar equivalents of the nitroxide to hemoglobin was added directly with mixing to a DCL-Hb
(8g/dl)in Lactated Ringers. The reaction mixture was allowed to react at 22°C with agitation until greater than 90% of the nitroxide was covalently linked to the DCL-Hb,usually within one hour. The unreacted nitroxide was then removed with a cross-flow membrane filtration system having a molecular- weight cut-off of 30,000 daltons by washing three(3) times with 10 volumes of Lactated Ringers. The retantate hemoglo¬ bin concentration is adjusted to between 7-14 g/dl, sterile filtered, and stored at 4°C. After transfusion, when the HRCS is fully oxygenated, the nitroxide is expected to function as a SOD-mimic and secondly as a catalase-mimic. As an SOD-mimic it dismutates the superoxide anion to hydrogen peroxide (See Equation [2] ) and consequently protect against the destruction of nitric oxide in the endothelium to prevent vasoconstriction. As a catalase-mimic it prevents hydrogen peroxide toxicity by converting the latter to harmless water (See Equation [3] ) .
As noted above, nitroxides have been covalently bound to hemoglobin to study the cooperative oxygen binding properties of the hemoglobin molecule itself. However, nitroxides have not been used with stabilized, i.e.. cross-linked, or polymerized, encapsulated, or conjugated hemoglobin solution that are physiologically compatible. The known chemistry of hemoglobin and nitroxides suggests that it is possible to perform similar nitroxide-labelling of hemoglobin that has been chemically cross-linked or cross-linked through recombi¬ nant techniques by selecting an available site on the hemoglobin molecule that is not blocked by the particular compound used to stabilize, polymerize, or conjugate the hemoglobin molecule(s). Because certain of the stabilized and polymerized forms of hemoglobin described below are currently involved in clinical trials, the attachment of nitroxides to these stabilized and polymerized hemoglobin- based oxygen carriers is described below in the context of the second, third, and fifth preferred embodiments to demon¬ strate that the oxygen detoxification function of this invention is applicable to the existing hemoglobin solutions. The nitroxide-labeling technology demonstrated here in the example of nitroxide-HBOC is readily applied to the production of other nitroxide-labelled macromolecules with useful antioxidant enzyme-mimetic activities, for example nitroxide-labelled serum albumin and nitroxide-labelled immunoglobulin. Forms of serum albumin which can readily be labelled by nitroxide by this technology are monomeric (normal) albumin, and albumin homodimers, oligomers, and aggregates (microspheres) .
The antioxidant enzyme mimic effect of a nitroxide- labelled macromolecule, hemoglobin, or the other appropriate macromolecules described here, has utility in other applica¬ tions, medical or otherwise, where antioxidant catalysis is useful.
MODES FOR CARRYING OUT THE INVENTION I. First Preferred Embodiment -- Nitroxide Labelled Con¬ tainers and Filters for HBOC
It is possible to provide the oxygen-detoxification function of this invention to existing HBOC solutions without chemically modifying the hemoglobin in these formulations. By covalently attaching nitroxides to a surface inside the vessel in which the HBOC is stored, this invention may alleviate the adverse physiological effects caused by oxygen toxicity that are observed with the existing formulations.
The container used with the hemoglobin-containing solutions that are the subject of this invention should be physiologically compatible having similar characteristics as any container to be used with intravenous fluids. Typically, glass or a biocompatible plastic is suitable. For the embodiments of the invention where a solution containing hemoglobin is placed in a container for any length of time, the container should be oxygen free and capable of being sealed to exclude oxygen. With a glass container, a tradi¬ tional stopper and closure means is sufficient. However, some of the flexible plastic containers currently available are oxygen permeable. In this case, a foil overwrap or other sealing mechanism may be used to prevent oxygen from contact¬ ing the hemoglobin in solution.
To apply a nitroxide to an inner surface of a container, a non-leaching layer of a nitroxide polymer or a nitroxide- doped copolymer is coated directly on the inner surface. Nitroxide-containing polymers can be created by a number of techniques based on generally known principles of polymeriza¬ tion as long as the stability of the free radical is main¬ tained in the polymerization process.
Also, the interior surface of an HBOC container may be modified to contain a coating layer of a substance that can bind a nitroxide, such as hydrophilic hydrazide groups which will react with the ketone or the aldehyde group of a nitroxide to form stable hydrazone derivatives. The coating reaction is straight forward. For example, the nitroxide (lOOmM) in acetate buffer at pH 5.0 is added to a hydrazide activated plastic container to facilitate the formation of a hydrazone linkage.
Once the container is prepared, a physiologically com¬ patible solution is added. This solution may be a stabilized and purified HBOC or the HRCS disclosed herein, but could also include any intravenous colloid or crystalloid solution that is desirable to co-infuse with hemoglobin. The solution is then maintained in an essentially oxygen-free environment. In addition to treating a surface inside a container, a filter-type cartridge, with a luer lock inlet and outlet, containing a gel or solid matrix upon which a nitroxide is immobilized may be used to remove reactive oxygen-derived reactive species while the hemoglobin solution passes through the cartridge. In these applications, the nitroxide is bound to a soft- or hard-gel matrix through which the HBOC passes, functioning essentially as a sterile in-line filter, prior to infusion. A variety of methods to attach small ligands, such as nitroxide, to a solid matrix are well known in the art of affinity chromatography, as are the techniques to chemically modify glass and plastic surfaces. Several types of matrices that are compatible with sterile solutions are known includ ing agarose gel, polysulfone-based material, latex, and others.
In the filter cartridge approach, the solid matrix is covalently linked with a nitroxide and contained in a filter housing or other such apparatus such that a hemoglobin solution can flow through the apparatus and be brought into contact with a nitroxide while being infused into a patient. A practical approach is to use a commonly available activated agarose gel as the matrix and contain the gel in a sterile luer lock cartridge. The cartridge is then simply inserted in the fluid administration line during the transfusion of a solution containing hemoglobin. In practice, the structure that comprises the filter housing in which the nitroxide and through which hemoglobin is passed can be provided by a variety of known structures. Referring now to Figure 12, housing 1 contains a nitroxide-labelled agarose gel. For example, a 4-bromoacetamido-TEMPO labelled ω-aminohexyl- agarose (See Figure 2A) a 1,4-bis(2,3-epoxypropoxy)butane agarose coupled with 4-amino-TEMPO (See Figure 2B) .
During the transfusion, the intravenous transfusion line containing a hemoglobin solution would be connected to the luer inlet 2 allowed to enter the housing 1 wherein the hemoglobin solution would encounter the nitroxide bound to the matrix 4 to remove the toxic oxygen-related species. The hemoglobin solution would then pass out of the cartridge through the luer outlet 3 and would be directly transfused into a patient. The electron resonance spectrum of 4-amino- TEMPO labelled epoxy-agarose is shown in Figure 2A. Alterna¬ tively, an ω-aminohexyl-agarose may be reacted with 4- (2- bromoacetamido) -TEMPO to form TEMPO labelled agarose. The electron spin resonance spectrum is shown in Figure 2B. An alternative would be to couple the 4-carboxyl-TEMPO to the amino-agarose with carbodiimide via a carboamide linkage. Conversely, the 4-amino-TEMPO is readily coupled to the carboxyl group on an agarose' gel using carbodiimide, for example, l-ethyl-3- (3-dimethylamino-propyl)carbodiimide.
The cartridge labelled with 4-amino-TEMPO prepared by circulating a lOOmM 4-amino-TEMPO (Sigma Chem. Co.) in a Lactated Ringers solution through an aldehyde AvidChrom Cartridge (Unisyn Tech. Inc.) at room temperature for one hour followed by the reduction with sodium cyanoborohydride for six (6) hours. The interior of the cartridge housing is thoroughly washed with Lactated Ringers.
The cartridge labelled with 3-amino-PROXYL may be simi¬ larly prepared by substituting 4-amino-TEMPO with 3-amino- PROXYL according to the procedure described above. II. Second Preferred Embodiment -- Nitroxide-Labelled
Stabilized Hemoglobin
To prevent dissociation of hemoglobin into its con¬ stituent subunits, hemoglobin is intramolecularly stabilized by chemical or recombinant cross-linking of its subunits. "Stabilized" hemoglobin is referred herein to describe hemoglobin monomers that are stabilized by chemical or recombinant cross-linking and also to describe dimers, trimers, and larger oligomers whose constituent hemoglobin molecules are stabilized by cross-linking with cyclodextrans and their sulfated derivatives.
A preferred technique and best mode for attaching nitroxide to stabilized hemoglobin is by the covalent attachment of the nitroxide to the S-93 sulfhydryl groups of the two S-chains of stabilized hemoglobin. Although specific labelling at the ,6-93 site has been demonstrated on native human hemoglobin for conformational studies (See review by McConnell et. al., Quart. Rev. Biophys. 3:91 (1970)), such a specific labelling of cross-linked hemoglobin has not been reported. As noted above, several types of hemoglobin-based oxygen carriers have been developed that are stabilized through chemical cross-linking with DBBF, diaspirin cross- linked hemoglobin and hemoglobin that is stabilized and oligomerized with o-raffinose.
The ring opened sugars described in my United States Patent No. 4,857,636 yield polyvalent aldehydes derived from disaccharides, oligosaccharides, or, preferably, tri- saccharides such as o-raffinose. These compounds function both to provide intramolecular stabilization (cross-linking) and intermolecular polymerization. By controlling the reaction disclosed in my earlier patent, the polyvalent aldehydes may be used to produce "stabilized" hemoglobin as defined above without polymerization. In another case, a nitroxide may be covalently bound to the stabilized hemoglo¬ bin or the polymerized hemoglobin. Therefore, the hemoglo¬ bin-based solutions that are stabilized using the polyvalent aldehydes are considered in the present embodiment as a "stabilized" hemoglobin and in the subsequent embodiment as a polymerized hemoglobin.
To demonstrate, that the S-93 site of the chemically modified hemoglobin has not been rendered sterically inacces¬ sible for nitroxide attachment, results are presented to confirm that a nitroxide may be covalently bound to the S-93 site of DBBF-Hb.
In this embodiment, DBBF-Hb is reacted with two types of nitroxides (TEMPO and PROXYL) which contain two types of sulfhydro group specific functional groups and have the following structural formula:
Figure imgf000040_0001
(I) (ID 4- (2-Bromoacetamido) -TEMPO 3-Maleimido-PROXYL 39
DBBF-Hb is prepared by cross-linking purified deoxygenat¬ ed hemoglobin in solution with bis(3,5 dibromosalicyl)fuma- rate by known techniques, and the resulting product is purified by column chromatography. The covalent attachment of 3-maleimido (2,2,5,5 -tetramethyl pyrrolidine-N-Oxyl) [3- maleimido-PROXYL] is accomplished by adding 2 molar equiva¬ lents of this nitroxide using methanol as the carrier solvent at a concentration of approximately lOOmM of 3-maleimido- PROXYL to 1ml of DBBF-Hb at a concentration of approximately 8 g/dl in Lactate Ringers. The DBBF-Hb is allowed to react at 22-23°C for approximately 30 minutes with mixing. The extent of cross-linking is estimated from the percent disappearance of the electron spin resonance signal intensity of the unreacted nitroxide. To remove the unreacted nitrox¬ ide, the reaction mixture was washed three (3) times with a 10 volume excess of Lactated Ringers using a Filtron stire cell with a 30 kilodalton cut-off nominal molecular weight limits (NMWL) polyethylene sulfone (PES) membrane (Filtron Technology Co.). The electron spin resonance measurements of the nitroxide-labelled hemoglobin was recorded with a Bruker ESR spectrometer. Figure 3A shows the electron spin resonance spectra of 4- (2-bromoacetamido) -TEMPO labelled DBBF-Hb. The electron spin resonance spectrum of DBBF-Hb that is similarly labelled with 3-maleimido-PROXYL is shown in Figure 3B.
In this embodiment, the nitroxide is covalently linked to the lone sulfhydro group on the two β-globin chains of hemoglobin. Thus, the nitroxide to hemoglobin-bound oxygen ratio is approximately 200 to 1 at 99.00% deoxy-hemoglobin because there are two nitroxides attached to the two β-globin chains of the hemoglobin. After transfusion, however, the deoxygenated HRCS picks up oxygen in the lung and the nitroxide to hemoglobin-bound oxygen ratio becomes approxi¬ mately 1 to 2 at 100% oxygenation because there are four oxygen molecules bound to the four globin chains of the hemoglobin with the two nitroxides remaining on the /3-globin chains.
Using a hemoglobin-to-nitroxide ratio of 1:2, greater than 90% of the nitroxide is covalently attached to the DBBF- Hb. DBBF-Hb may also be covalently labelled with a spacer group (e.g., an extra methyl group) between the maleimido and PROXYL moieties (i.e., 3-maleimidomethyl-PROXYL) which would exhibit a resonance spectrum similar to that of Figure 3B. It is noteworthy that other nitroxides may be covalently at¬ tached to specific amino-groups in the DPG binding site (e.g., jS-Val-1 /3-Lys-82 and oc-Lys-99) or may be attached to the remaining 40-plus surface lysine e-amino groups on hemoglobin. Isothiocyanate derivatives of the TEMPO and PROXYL nitroxides are also reactive with the amino group. For example, 4-isothiocyanate-TEMPO may be added to hemoglo¬ bin at a molar ratio of approximately 10:1. Resonance spectrum (not shown) of hemoglobin labelled with this nitroxide at other sites is similar to that shown in Figure 3A.
The ability to attach nitroxides at several sites of DBBF-Hb suggests that recombinant hemoglobin that is stabi¬ lized with alpha-globin dimers (D. Looker et.al. NATURE 356:258 (1992)) may be similarly labelled with a nitroxide. It is also possible to prepare a DBBF analogue of a nitroxide labelled cross-linking agent such as a TEMPO labelled succinate (See U.S. Patent No. ' 4,240,797) .
Figure 4 is ESR spectra of (A) 2- (bromoacetamido) -TEMPO, (B) 2- (bromoacetamido) -TEMPO-labelled HBOC and (C) 1SND17 TEMPOL (TEMPOL: 4-hydroxy-2,2,6,6-tetramethylpiperidine-l- oxyl) in Lactated Ringer's solution recorded at room tempera¬ ture. The difference in Figure 4A and 4B represents the difference in the mobility of a small molecular weight nitroxide to that of a nitroxide covalently attached to a macromolecule such as hemoglobin. Figure 4C shows that a stable isotope nitrogen 1SN with a nuclear spin of 1/2 yields two resonance peaks and that natural-isotopic 14N with a nuclear spin of 1 yields three resonance peaks (compare (4A to 4C) . In the set of experiments described here the separa¬ tion of these resonance peaks is used to demonstrate the enzyme-mimic and in vivo and in vi tro oxidation/reduction reactions of small and macromolecular weight nitroxides.
Nitroxide labelled HBOC with different molar ratios of nitroxide to hemoglobin are prepared as follows. 2, 4, and 8 molar equivalents of 4- (2-bromoacetamido) -TEMPO, were added as solid powder directly into three separate 15 ml Vacutain- ers in a clean hood. After replacing the rubber septum, 4- (2-bromoacetamido) -TEMPO was subsequently dissolved in 200 ul chloroform. The Vacutainers were then connected to high vacuum (5 mm Hg) via a 27 gauge needle through the rubber septum and the chloroform was removed leaving a thin film of 4- (2-bromoacetamido) -TEMPO coating the lower half of the Vacutainer. After introducing the appropriate amount of HBOC via sterile transfer through the rubber septum, the solutions were allowed to react at room temperature with intermittent vortex mixing at approximately 5 minute intervals for 1/2 hour (not all solids were dissolved in the 4 and 8 molar ratios of nitroxide to hemoglobin) , the Vacutainers were then left at 4 degrees C in a refrigerator over night. Vortex mixing at room temperature was resumed the next morning for another 1/2 hour until all solids of 4- (2-bromoacetamido) - TEMPO had visually disappeared from the surface of the Vacutainer.
The reaction mixtures and the control, were then trans¬ ferred to a sterile dialyzing tube and dialyzed against Lactated Ringers until no unlabelled free 4- (2-bromoacet¬ amido) -TEMPO electron spin resonance (ESR) signals could be detected. The ESR spectra of 4- (2-bromoacetamido) -TEMPO- labelled HBOC at 2, 4, and 8 molar equivalents 4- (2-bromo¬ acetamido) -TEMPO to Hb are shown in Figures 5A-5C respective- ly. At 2 molar equivalents of 4- (2-bromoacetamido) -TEMPO to hemoglobin, the ESR spectra are essentially the same with or without dialysis indicating the covalent labeling is quanti¬ tative. The two SH- groups on the beta globulin chains appear to be the site of covalent attachment in the case of HBOC (this can be confirmed by selective blocking of 4- (2- bromoacetamido) -TEMPO labeling with N-ethyl-maleimide or globulin chain analysis by reverse phase HPLC) . It is noteworthy that the ESR signal intensity (peak Mo) ratios for 2, 4, and 8 are in approximately the same ratio as the spectra were recorded at proportionately decreasing instru¬ ment sensitivity.
Furthermore, it is expected that more 4- (2-bromoaceta¬ mido) -TEMPO could be attached to Hb at even higher molar ratios, for example as radiation-protective agents in vivo.
The preferred molar of nitroxide to hemoglobin in the blood substitute formulations is 8:1 as described below.
Referring to Figure 6, an ESR spectrum of a mixture of 4-
(2-bromoacetamide) -TEMPO-labelled HBOC and 15ND17-TEMPOL wherein the center peak of the 4- (2-bromoacetamido) -TEMPO
(indicated by down arrow) and the high field peak of 15ND 17
TEMPOL (indicated by the up-arrow) were adjusted to similar intensity.
The separation of the resonance peaks permits the simul¬ taneous monitoring of free radical or enzyme mimic activities involving the small molecular weight nitroxide (TEMPOL) and its macromolecular conjugate in both in vi tro and in vivo (murine) reactions. For example, the in vivo plasma half- life of the two nitroxides was compared by referring to the unique spectral characteristics of the different nitroxides. Specifically, the in vivo ESR studies of hemoglobin-based solutions, on the mouse were performed using a nitroxide to hemoglobin ratio of 8:1 (see Fig. 5C) to take advantage of its high ESR signal intensity. First, the approximate plasma half-life of a small molecular "weight nitroxide (15ND17-TEMPOL see Fig. 4C) and a large molecular weight 4- (2-bromoaceta¬ mido) -TEMPOL-labelled HBOC (see Fig. 4B) are determined by preparing a mixture of the two and adjusting the ESR signal intensity to be approximately the same (see Fig. 6) . 0.5 ml of the mixture was injected under anesthesia into a distended mouse tail vein under a heat lamp. The mouse tail was inserted into an ESR cavity and the spectrum was recorded within 10 min. after injection (see Fig. 7A) .
Referring to Figure 7A, 7B, and 7C the 1SND17-TEMP0L signal could not be detected, however, the 4- (2-bromoacet¬ amido) -TEMPO-labelled HBOC was clearly resolved (see Fig. 7B and 7C for plasma half-life studies where 7C is a continua¬ tion of 7B) . Since the vasoconstrictive effect of HBOC is reported to be fully developed during the first 5-15 min. of bolus injection of an HBOC in rats, the participation of the nitroxide-labelled HBOC in free radical redox-reactions immediately after transfusion in a mouse was measured. The tail vein of female CH3 mouse was cannulated under anesthesia with 80% nitrous oxide, 20% oxygen, and 3% isofluorane. Under a heat lamp the mouse tail vein became visibly distend¬ ed, a cannula consisting of a 30 gauge hypodermic needle attached to a one foot length of polyethylene tubing was inserted into the tail vein and held in place by cyanoacry- late glue. For in vivo ESR measurements, the cannulated mouse was transferred under anesthesia to a 50 ml conical centrifuge tube modified to allow the tail to protrude from the conical end and to allow a continuous flow of anesthetic gas from the opening end of the tube. The tail was inserted into a plastic tube which was then fitted into a TE 102 cavity. The cannula was flushed periodically with heparin (100 unit/ml) to ensure patency. The cannula was near the root of the tail and was kept outside of the ESR cavity so that a pure signal from the tail could be measured immediate¬ ly after bolus injection. 0.5 ml of samples (see Fig. 8) were injected via the cannula and the spectrometer was set for a repeat scanning mode at 1/2 min. intervals (see Figs. 8A and 8B) . In Fig. 8A the magnetic field was increased by two Gauss, and in Fig. 8B the magnetic field was decreased by two Gauss, to superimpose the resonance spectra. The 1SND17- TEMPOL signal disappeared within 2.5 minutes after injection. During the same time period the 4- (2-bromoacetamido) -TEMPOL- labelled HBOC also decreased at a similar rate.
However, the nitroxide-HBOC signal were shown to be stable in plasma (Fig. 8B) . Therefore, Fig. 8B together with results from Fig. 7 show that the nitroxide-labelled to macromolecules such as HBOC has considerably longer plasma half-life as compared to small molecular weight nitroxide (e.g.. 15ND17-TEMPOL) .
The observed nature of the free radical reaction involves two pathways:
1. the rapid phase appears to involve the free radical (e.g. superoxide) oxidation of the nitroxide to its oxoammonium cation intermediate followed by the reduction of the oxoammonium cation to its stable hydroxylamine derivative of the nitroxide. Such reduction involves the participation of either one or two reducing equivalents (e.g. NADH) present in the vascular compartment. The reduction of nitro¬ xide to its hydroxylamine would lead to a rapid reduction in ESR signal intensity, in the case of 8:1 molar ratio of 4- (2-bromoacetamido) -TEMPO- labelled HBOC represents approximately 25% of the 4- (2-bromoacetamido) -TEMPO on the HBOC. This phase involves both small molecule and macromolecular nitroxide.
2. the slow phase appears (see Figure 8B) to represent the antioxidant enzyme-mimic activities of the remaining 75% of 4- (2-bromoacetamido) -TEMPO on the HBOC in accordance with the reaction mechanism wherein the nitroxide is involved in the cyclic- free radical reactions for example the SOD-mimic reaction. Where the nitroxide free radical is essentially unconsumed as a SOD-mimic, the slow rate of decrease of the ESR signal intensity can be attributable primarily to the reaction mechanism described above and secondarily to the decrease in
HBOC concentration as it is slowly eliminated from the vascular compartment as a function of its plasma half-life.
This result demonstrates the utility of nitroxide labelled HBOC in detoxifying free radicals in vivo. This utility is defined in terms of providing short term (in minutes) scavenging of free radicals and persistent (in hours) protection against oxidant reactions by nitroxides acting as enzyme mimics in vivo.
Based on the analysis of the spectra in Figure 8, the oxidation/reduction (redox) cycling reactions involve approximately 73% of 4- (2-bromoacetamido) -TEMPO-labelledHBOC remaining in its free radical state. This indicates that TEMPOL participates in in vivo redox-reactions within the confines of the vascular space.
III. Third Preferred Embodiment -- Nitroxide-Labelled Polymers of Stabilized Hemoglobin While it is possible to produce dimers of stabilized hemoglobin from cross-linked monomers, it is also possible to produce hemoglobin polymers from stabilized or native hemoglobin. Solutions of hemoglobin polymers contain a mixture of monomers, dimers, trimers, tetramers, and other oligomers. Solutions containing polymerized hemoglobins used as an HBOC generally have longer plasma circulation times and higher oxygen carrying capacities as compared to stabilized monomeric hemoglobin. Such polymerized hemoglobin may be prepared by a number of pathways using several different polymerizing agents. (See. • U.S. Pat. Nos. 4,001,200, 4,857,636, and 4,826,811) . The preferred method of introduc¬ ing a nitroxide to a solution of polymerized hemoglobin is again by covalently attaching a nitroxide to the β-93 sulfhydryl groups of the two /S-globin chains of hemoglobin. These sulfhydryl groups are not known to be involved in the stabilization or polymerization processes. Consequently, the nitroxide is preferably covalently attached to hemoglobin before the stabilization and polymerization of the hemoglobin monomers.
For example, nitroxide is covalently attached to DBBF-Hb according to the procedure described in the second embodiment above, followed by polymerization with glutaldehyde according to the procedure described in Sehgal et. al. U. S. Patent No. 4,826,811. Figure 4B is an electron spin resonance spectra of the DBBF-Hb labelled with 3-maleimido-PROXYL and polymer¬ ized with glutaldehyde. Similarly, DBBF-Hb that is polymer¬ ized with glutaldehyde may be labelled with 4-(2-bromo- acetamido) -TEMPO by the same method.
Using a similar approach, a polymerized hemoglobin intermediate, such as a glutaldehyde-polymerized, an o- raffinose-polymerized, or an o-cyclodextran-polymerized hemoglobin intermediate that contains unreacted aldehyde groups, may be used for covalent attachment of either 4- amino-TEMPO or 3-amino-PROXYL via reductive amination to yield a nitroxide-labelled hemoglobin polymer. With reduc¬ tive amination, the sequence and timing of the reaction are important. The 4-amino-TEMPO is added to glutaldehyde- polymerized hemoglobin after completion of polymerization, but prior to the reduction reaction that results in covalent attachment of the nitroxide to the polymerized hemoglobin. Likewise, the nitroxide labelling of a o-raffinose poly¬ merized hemoglobin may be accomplished by the addition of either 4-amino-TEMPO or 3-amino-PROXYL prior to reductive amination. For example, 4-amino-TEMPO labelled o-raffinose polymerized hemoglobin is prepared according to the procedure described in my United States Patent No. 4,857,636 except that 6 molar equivalents of 4-amino-TEMPO is added after the completion of the polymerization and prior to the reduction with 20 molar excess of borane dimethylamine complex. As described therein, hemoglobin may be cross-linked and polymerized using polyvalent aldehydes derived from disaccha- rides or ring-opened sugars including, oligosaccharides, or preferably, trisaccharides such as o-raffinose. Likewise, monosaccharides may be used to stabilize and polymerize hemoglobin although the higher molecular weight sugars are preferred. The resonance spectrum of a dialyzed and washed o-raffinose polymerized hemoglobin labelled with 4-amino- TEMPO was shown in Figure 9A.
To increase the yield of hemoglobin oligomers (Hbn where n=2-4) of the polymerized hemoglobin, it is desirable to increase the valance of the polyaldehyde of the cross-linker, with the use of α-cyclodextran, /S-cyclodextran, and y- cyclodextran, as well as their sulfate derivatives which represents 6-, 7-, and 8-cyclized glucose molecules, the ring opened α-cyclodextran, S-cyclodextran, and γ-cyclodextran have 12, 14, and 16 reactive aldehyde groups respectively. These ring-opened cross-linkers can be used to cross-link and polymerize hemoglobin to produce polymerized hemoglobin which is rich in oligomers. The unreacted aldehyde, as described above, may be utilized to covalently attached to an amino- nitroxide, for example, 4-amino-TEMPO or 3-amino-PROXYL.
Furthermore, the ring-opened sulfate derivatives, for example, the sulfated α-cyclodextran will be an effective cross-linker for two additional reasons: (1) the sulfate groups will mimic the activity of DPG in lowering the oxygen affinity of the cross-linked hemoglobin, thus improving oxygen transport properties, and (2) the sulfate groups will serve as affinity labels which will complex multiple (e.g. , n=2-4) hemoglobins to initially form a "cluster." Once the "cluster" complex is formed, the aldehyde groups on the cyclodextran will be brought to close proximity with the NH2 groups within the DPG binding sites, thus promoting the covalent intra-subunit and inter-molecular cross-linking of hemoglobin resulting in an increased yield of hemoglobin oligomers. In addition to antioxidant enzyme-mimic activi¬ ties, the ring-opened cyclodextran polymerized and nitroxide- labelled hemoglobin will also have improved yield and composition as compared to ό-raffinose and glutaldehyde polymerized hemoglobin.
IV. Fourth Preferred Embodiment -- Nitroxide-Labelled Lipo¬ some-Encapsulated Hemoglobin
Liposomes are particles which are formed from the aggregation of amphophilic molecules to form a bilayer structure in a hollow spherical shape with the polar sides facing an internal water compartment and external bulk water. Several acceptable methods for forming liposomes are known in the art. Typically, molecules form liposomes in aqueous solution like dipalmitoyl phosphatidylcholine. Liposomes may be formulated with cholesterol for added stability and may include other materials such as neutral lipids, and surface modifiers such as positively or negatively charged compounds. The preferred liposomes are small unilamellar-bilayered spherical shells.
A method for encapsulating hemoglobin in a liposome is also known (See Farmer et. al., United States Patent No. 4,911,921). For the purpose of this invention, a number of approaches may be used to introduce the nitroxide-based oxygen detoxification function to a solution of liposome- encapsulated hemoglobin. For example, it is possible to use nitroxide-labelled native hemoglobin, or a nitroxide-labelled stabilized hemoglobin as disclosed above, as the starting material and then performing the process of liposome encapsu¬ lation of the nitroxide-labelled hemoglobin by known tech¬ niques. In the present embodiment, purified hemoglobin may also be coencapsulated with a membrane impermeable nitroxide such as TEMPO-choline chloride disclosed for a spin membrane immunoassay in Hsia et. al. United States Patent No. 4,235,792.
Also, any purified hemoglobin may be encapsulated with a liposome comprised of nitroxide-labelled fatty acids (e.g.. 7-DOXYL-stearate, 12-DOXYL-stearic acid, and 16-DOXYL- stearate) , cholestane, an analogue of cholesterol (e.g.. 3- DOXYL-cholestane) , or phospholipid (e.g.. 12-DOXYL-stearate- labelled phosphatidylcholine) . The preparation of hemoglobin encapsulated in a liposome comprised of 3-DOXYL-cholestane labelled may be prepared by a method analogous to that described in Tabushi et. al., (J. Am. Chem. Soc. 106: 219 (1984) ) . A 5ml chloroform solution containing lipid composi¬ tions, including DOXYL labelled stearic acid and/or chol¬ estane, as specified below were first dried in a stream of nitrogen to remove the solvent. Next, the residues were dried in vacuo and the resulting film was suspended in 2ml of hemoglobin (24g/dl) in a Lactated Ringers solution. The lipid concentration in the dispersion is 100 mM. The liposome encapsulated hemoglobin is then rotated and incubat¬ ed preferably at 37°C until all lipids are dispersed to form multilamellar vesicles. The resulting solution containing multilamellar liposome encapsulated hemoglobin and free unencapsulated hemoglobin is then forced through a micro- fluidizer to form 0.2 micron liposomes according to the procedure of Cook et.al. (See U.S. Pat.4,533,254) . The molar ratio of dipalmitoyl phosphatidylcoline: cholesterol: dipalmitidyl phosphatidic acid: 3-DOXYL-cholestane in the liposome is 0.5:0.4:0.02:0.07. The resonance spectrum of the resulting 3-DOXYL-cholestane labelled liposome-encapsulated hemoglobin is shown in Figure 10A. In this configuration, the nitroxide is intercalated into the liposome membrane and can be found at both the inner and outer surface of the lipid bilayer water interface. Substituting the 3-DOXYL-cholestane with 16-DOXYL-stearic acid in the lipid composition shown in Figure 10A results in an electron resonance spectrum shown in Figure 10B. The mobility of the nitroxide as reflected from the resonance spectrum is consistent with the interpretation that the DOXYL-moiety of the stearic acid is located predomi¬ nately in the hydrophobic interior of the lipid bilayer. With the addition of both the 3-DOXYL-cholestane and 16- DOXYL-stearate to the lipid composition at the same molar ratio, the resonance spectrum of the double nitroxide labelled liposome encapsulated hemoglobin is shown in Figure IOC. The resonance spectrum of Figure IOC is a composite of Figures 10A and 10B because the nitroxides in this embodiment are located at both the membrane-water interface and its hydrophobic lipid bilayer interior. By placing the nitroxide in both locations, this embodiment provides the oxygen detoxification function at both the lipid bilayer hydrophobic interior and the membrane-water interface thus providing the added benefit of an additional reserve of oxygen-detoxifica¬ tion capacity for the encapsulated hemoglobin. V. Fifth Preferred Embodiment -- Nitroxide-Labelled Conju¬ gated Hemoglobin
A physiologically compatible solution of conjugated hemoglobin is produced by forming a conjugate of hemoglobin and a biocompatible macromolecule used as a plasma expander. Plasma expanders, such as dextran (Dx) , polyoxyethylene (POE) , hydroxylethyl starch (HES) , are used to increase the circulation half life of hemoglobin in the body. In this state, the hemoglobin molecules together with the bio¬ compatible macromolecule are collectively referred to as a hemoglobin conjugate. There are a number of convenient methods to incorporate a nitroxide into a hemoglobin conju¬ gate. For example, one may simply substitute the hemoglobin to be conjugated with a nitroxide-labelled hemoglobin such as TEMPO labelled DBBF-Hb. This can be accomplished by substi- tuting hemoglobin or pyridoxylated hemoglobin with 3-malei- mido-PROXYL-DBBF-Hb or 4- (2-bromoacetamido) -TEMPO-DBBF-Hb in the preparation of conjugated hemoglobin.
4-Amino-TEMPO labelled dextran conjugated hemoglobin is prepared in accord with the procedure described by Tarn et. al. (Proc. Natl. Acad. Sci., 73:2128 (1976)). Initially, an 8% hemoglobin solution in 0.15 M NaCl and 5 mM phosphate buffer, pH 7.4 is conjugated to periodate-oxidized dextran to form a Schiff-base intermediate. Twenty molar equivalents of 4-amino-TEMPO is added to hemoglobin to form the Schiff-base between the nitroxide and the remaining reactive aldehyde groups on the dextran. After a 30 minute of incubation at 4°C, a 50 molar equivalent of dimethylamine borane in water is added. The solution is incubated for a further 2 hours at 4°C. Afterwards, the solution is dialyzed, reconstituted with Lactate Ringers buffer and sterile filtered with Filtron membrane filtration units (Filtron Technology Co.). The electron spin resonance spectrum of the 4-amino-TEMPO labelled dextran-conjugated hemoglobin is a sharp asymmetric triplet reflecting a high degree of motional freedom (See Figure 11) . The increased mobility of the TEMPO covalently attached to the Dextran is consistent with the nitroxide linked to a flexible polysaccharide dextran chain as compared to that of a tightly folded hemoglobin molecule (See Figures 3A and 3B) . Thus, resonance spectrum in Figure 11 demon¬ strates that a novel nitroxide labelled dextran conjugated hemoglobin has been prepared.
VI. Sixth Preferred Embodiment -- Enzyme-Mimetic Activity of
Nitroxide-Labelled Albumin
As noted above, nitroxides (e.g.. TEMPOL) have been shown to have catalytic activity which mimics that of SOD, the metalloenzyme which dismutes superoxide to hydrogen peroxide Furthermore, in biological systems nitroxides can interact with peroxidases and pseudoperoxidases to achieve an activity mimicking that of catalase, the enzyme which converts hydrogen peroxide to oxygen. The biological effects of nitroxide include contributing to protection against cytotox- icity of reactive oxygen species, apparently by reducing oxidative stress, for example, nitroxides protect against damage by ionizing radiation in vivo and in vi tro. Thus, nitroxides when administered in vivo, display complex antioxidant enzyme-mimetic activities.
When injected intravenously, TEMPOL has been shown to have very short plasma half-life. Due to its molecular size and charge characteristics, it readily leaves the vascular space. In certain medical applications, other than those involving HBOC or HRCS, however, it may be desirable to have an antioxidant enzyme mimic which persists in the vascular space. This may be achieved by attaching a nitroxide compound to a macromolecule other than hemoglobin and which is biologically safe and has a desirable plasma half-life. An example of such a desirable macromolecules is human serum albumin (HSA) .
Serum albumin is a plasma protein with multiple ligand- binding sites and is the transport protein for many ligands in the blood. Nitroxides can bind specifically to human serum albumin at a number of specific ligand binding sites, or non-specifically.
Nitroxide-labelled albumin may be used in vivo to provide protection against cellular ■ damage by reactive oxygen species. Nitroxide-albumin may be used either alone or in combination with a low molecular weight nitroxide compound, e.g.. TEMPOL. Nitroxide-labelled albumin is also available as an "improved" version of albumin (i.e.. improved by having antioxidant activity) with utility in any application where albumin is now conventionally used, including as a parenteral colloid solution, in biomaterials, in biocompatible surface coatings, etc.
The albumin may be obtained from plasma or may be produced by recombinant genetic means. HSA may be used in a variety of forms, including monomers (normal plasma form) , homodimers, oligomers, and aggregates (microspheres) . Specific labelling of the albumin with a nitroxide may be achieved at several binding sites, including bilirubin, FFA, indole, or Cu++ binding site by using nitroxide compounds which have been activated in order to confer upon them binding specificity of the relevant site on the protein. A preferred example is 2, 2, 6, 6-tetramethyl-l-oxyl-4-piperi- dylidene succinate (TOPS) nitroxide covalently bound to the primary bilirubin-binding site of HSA. Non-specific label¬ ling of albumin may be achieved at approximately 50 accessi¬ ble amino groups.
VII. Seventh Preferred Embodiment -- Nitroxide-Labelled Immunoglobulin
As in the above embodiments, certain nitroxides have been shown to have very short plasma half-life when injected intravenously. Due to the desire to have an antioxidant enzyme mimic with a long plasma half-life, a nitroxide compound may be attached to an immunoglobulin to provide long-lasting antioxidant enzyme mimic activity.
Immunoglobulins are a class of plasma proteins produced in the B-cells of the immune system and which are character¬ ized by two specific ligand binding sites (the antigen- binding sites) . Nitroxides have been used in the past as probes in research on hapten-binding specificity and affinity of immunoglobulins during the primary and secondary immune response.
As with the above-embodiment describing nitroxide- labelled albumin, the nitroxide-labelling technology demon¬ strated above in the example of nitroxide-HBOC is readily applied to the production of nitroxide-labelled immunoglob¬ ulins.
Nitroxide-labelled immunoglobulins may be used in vivo to provide protection against cellular damage by reactive oxygen species. Nitroxide-immunoglobulin may be used either alone or in combination with a low molecular weight nitroxide compound to provide extended antioxidant activity with an extended plasma half-life.
Nitroxide-labelled immunoglobulin may be prepared by specific labelling of the immunoglobulin itself or by covalently labelling at a hapten-binding site. To avoid clearance of the nitroxide-labelled immunoglobulin as part of the body's natural immune response, one may use immuno¬ globulin fragments, for example, (Fab)2 produced by cleaving the immunoglobulin according to known techniques with non¬ specific-labelling, a preferred molar ratio of nitroxide:- immunoglobulin is up to 60:1.
Although the invention has been illustrated by the specific embodiments described above, due to variety of forms of physiologically compatible hemoglobin and the structural diversity of the stable nitroxide-free radicals, a number of variations on the above embodiments are possible without departing from the basic spirit of the invention as described by the following claims.

Claims

I Claim as follows:
1. A physiologically compatible hemoglobin-based solution characterized by stabilized hemoglobin, and a nitroxide covalently bound to the stabilized hemo¬ globin.
2. The hemoglobin-based solution of Claim 1 wherein the hemoglobin is stabilized by cross-linking.
3. The hemoglobin-based solution of Claim 1 wherein the hemoglobin is recombinant and stabilized with alpha-globin dimers.
4. The hemoglobin-based solution of Claim 2 wherein the hemoglobin is cross-linked using a polyvalent aldehyde derived from a ring-opened linear sugar.
5. The hemoglobin-based solution of Claim 2 wherein the hemoglobin is cross-linked using a polyvalent aldehyde derived from a ring-opened cyclic sugar.
6. The hemoglobin-based solution of Claims 1, 2, 3, 4, or 5, wherein the nitroxide has the structure
o
Figure imgf000063_0001
where R-_ - R4 are alkyl groups of 1-4 carbon atoms and A is the remaining members of a 5-membered ring.
7. The hemoglobin-based solution of Claim 6 wherein the nitroxide is 2,2,5,5-tetramethylpyrrolidine-N-oxyl.
8. The hemoglobin-based solution of Claim 1, 2, 3, 4, or 5 wherein the nitroxide has the structure o
Figure imgf000063_0002
where R-, - R4 are alkyl groups of 1-4 carbon atoms and A is the remaining members of a 6-membered ring.
9. The hemoglobin-based solution of Claim 8 wherein the nitroxide is 2,2,6,6-tetramethylpiperdine-N-oxyl.
10. A physiologically compatible hemoglobin-based solution characterized by a polymer hemoglobin, and a nitroxide covalently bound to the polymerized hemoglobin.
11. The hemoglobin-based solution of Claim 10 wherein the hemoglobin polymer comprises a polyvalent aldehyde derived from a ring-opened linear sugar.
12. The hemoglobin-based solution of Claim 11 wherein the hemoglobin polymer comprises a polyvalent aldehyde derived from a ring-opened cyclic sugar.
13. The hemoglobin-based solution of Claims 10, 11, or 12 wherein the nitroxide has the structure
Figure imgf000064_0001
where Rx - R4 are alkyl groups of 1-4 carbon atoms and A is the remaining members of a 5-membered ring.
14. The hemoglobin-based colution of Claim 13 wherein the nitroxide is 2,2,5,5-tetramethylpyrrolidine-N-oxyl.
15. The hemoglobin-based solution of Claims 10, 11, or 12 wherein the nitroxide has the structure
M. c
P.. A^
where R-_ - R4 are alkyl groups of 1-4 carbon atoms and A is the remaining members of a 6-membered ring.
16. The hemoglobin-based solution of Claim 15 wherein the nitroxide is 2,2,6,6-tetramethylpiperdine-N-oxyl.
17. A physiologically compatible hemoglobin-based solution characterized by a physiologically compatible liposome, hemoglobin encapsulated in the liposome, and a nitroxide encapsulated in the liposome.
18. The hemoglobin-based solution of Claim 17 wherein the nitroxide is intercalated in the liposome membrane.
19. The hemoglobin-based solution of Claim 18 wherein the hemoglobin is stabilized by cross-linking or polymeriza¬ tion.
20. The hemoglobin-based solution of Claim 17 wherein the liposome is comprised of nitroxide-labelled fatty acids, cholestone, or phospholipids.
21. The hemoglobin-based solution of Claims 17, 18, 19, or 20 wherein the nitroxide has the structure
Figure imgf000066_0001
* * ■*-
Figure imgf000066_0002
where Rx - R4 are alkyl groups of 1 -4 carbon atoms and A is the remaining members of a 5 -membered ring .
22. The hemoglobin-based solution of Claim 21 wherein the nitroxide is 2,2,5,5-tetramethylpyrrolidine-N-oxyl.
23. The hemoglobin-based solution of Claims 17, 18, 19, or 20 wherein the nitroxide has the structure
o
) •
where j - R4 are alkyl groups of 1-4 carbon atoms and A is the remaining members of a 6-membered ring.
24. The hemoglobin-based solution of Claim 23 wherein the nitroxide is 2,2,6,6-tetramethylpiperdine-N-oxyl.
25. A physiologically compatible hemoglobin-based solution comprising stabilized hemoglobin covalently bound to a nitroxide and forming a conjugate with albumin, dextran, poly- oxyethylene, or hydroxyethyl starch.
26. The conjugated hemoglobin-based solution of Claim 25 wherein the nitroxide has the structure
Figure imgf000068_0001
where R1 - R4 are alkyl groups of 1-4 carbon atoms and A is the remaining members of a 5-membered ring.
27. The conjugated hemoglobin-based solution of Claim 26 wherein the nitroxide is 2,2,5,5, -tetramethylpyrrolidine- N-oxyl.
28. The conjugated hemoglobin-based solution of Claim 25 wherein the nitroxide has the structure
^ ' •— - v where Rx - R4 are alkyl groups of 1 -4 carbon atoms and
A is the remaining members of a 6 -membered ring .
29 . The hemoglobin conjugate of Claim 28 wherein the nitroxide is 2 , 2 , 6 , 6 -tetramethylpiperdine-N-oxyl .
30. A method to produce a physiologically compatible solution containing stabilized hemoglobin characterized by the steps of: covalently binding a nitroxide to stabilized hemoglo- bin, and containing the stabilized hemoglobin solution in an environment that is substantially free of oxygen.
31. The method of Claim 30 wherein the nitroxide is covalently bound to a site on the stabilized hemoglobin comprising a sulfhydro group, a 093 site, or a reactive amino group.
32. A method to produce a physiologically compatible solution containing a biologically compatible macromole¬ cule characterized by: providing a physiologically compatible solution containing a biologically compatible macromolecule covalently bound to a nitroxide where the nitroxide is reactive with free radical species in the vascular compartment of an organism.
33. The method of Claim 32 wherein the macromolecule is selected from among the group consisting of hemoglobin, albumin, or immunoglobulin.
34. The method of Claim 33 wherein the macromolecule is stabilized hemoglobin.
35. The method of Claim 33 wherein the macromolecule is polymerized hemoglobin.
36. A method to produce a liposome-encapsulated hemoglobin solution characterized by encapsulating a nitroxide and hemoglobin inside a liposome.
37. The method of Claim 36 wherein the nitroxide is covalently bound to the hemoglobin.
38. A container for physiologically compatible hemoglobin solutions characterized by a nitroxide coated on a surface inside the container.
39. The container of Claim 38 wherein the nitroxide is coated on the surface of a matrix located inside the container.
40. The container of Claims 38 or 39 wherein the nitroxide has the structure
o
*.
Figure imgf000071_0001
where R1 - R4 are alkyl groups of 1-4 carbon atoms and A is the remaining members of a 5-membered ring.
41. The container of Claim 40 wherein the nitroxide is 2,2,5,5-tetramethylpyrrolidine-N-oxyl.
42. The container of Claim 38 or 39 wherein the nitroxide has the structure o
- ' *
Figure imgf000071_0002
where R-. - R4 are alkyl groups of 1 -4 carbon atoms and A is the remaining members of a 6 -membered ring .
43. The container of Claim 42 wherein the nitroxide is 2,2,6,6-tetramethylpiperdine-N-oxyl.
44. A filter having a housing for physiologically compati¬ ble hemoglobin-based solutions characterized by a nitroxide bound to a matrix contained within the housing.
PCT/US1994/009246 1993-08-16 1994-08-16 Composition and methods using nitroxides to avoid oxygen toxicity WO1995005397A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK94927922T DK0714407T3 (en) 1993-08-16 1994-08-16 Composition and method for avoiding oxygen toxicity by nitroxides
ES94927922T ES2114227T3 (en) 1993-08-16 1994-08-16 COMPOSITION AND METHODS THAT USE NITROXIDES TO AVOID OXYGEN TOXICITY.
JP50714895A JP3628019B2 (en) 1993-08-16 1994-08-16 Composition and method for preventing oxygen toxicity using nitroxide
DE69408539T DE69408539T2 (en) 1993-08-16 1994-08-16 COMPOSITIONS AND METHODS FOR THE PREVENTION OF OXYGEN TOXICITY BY MEANS OF NITROXIDES
EP94927922A EP0714407B1 (en) 1993-08-16 1994-08-16 Composition and methods using nitroxides to avoid oxygen toxicity
GR980400805T GR3026609T3 (en) 1993-08-16 1998-04-10 Composition and methods using nitroxides to avoid oxygen toxicity
HK98106880A HK1007858A1 (en) 1993-08-16 1998-06-26 Composition and methods using nitroxides to avoid oxygen toxicity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10754393A 1993-08-16 1993-08-16
US08/107,543 1993-08-16
US08/291,590 US5591710A (en) 1993-08-16 1994-08-15 Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US08/291,590 1994-08-15

Publications (1)

Publication Number Publication Date
WO1995005397A1 true WO1995005397A1 (en) 1995-02-23

Family

ID=22317141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009246 WO1995005397A1 (en) 1993-08-16 1994-08-16 Composition and methods using nitroxides to avoid oxygen toxicity

Country Status (13)

Country Link
US (5) US5591710A (en)
EP (2) EP0770627A1 (en)
JP (1) JP3628019B2 (en)
CN (3) CN1046635C (en)
AT (1) ATE163186T1 (en)
CA (1) CA2169178A1 (en)
DE (1) DE69408539T2 (en)
DK (1) DK0714407T3 (en)
ES (1) ES2114227T3 (en)
GR (1) GR3026609T3 (en)
HK (1) HK1007858A1 (en)
TW (2) TW381022B (en)
WO (1) WO1995005397A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029974A2 (en) * 1995-03-31 1996-10-03 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
DE19514088A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate for the treatment of inflammation, infection and / or skin diseases
WO1996040127A1 (en) * 1995-06-07 1996-12-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nitroxides as protectors against oxidative stress
WO1998034955A1 (en) * 1997-02-06 1998-08-13 Duke University Medical Center No-modified hemoglobins and uses therefor
EP1029551A2 (en) * 1999-02-08 2000-08-23 Hokkaido University Nitrogen monoxide metabolite-polyoxyalkylene-hemoglobin complex
SG95590A1 (en) * 1995-03-31 2003-04-23 Synzyme Technologies Inc Compositions and method utilizing nitroxides in combination with biocompatible macromolecules
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
WO2004100995A1 (en) * 2003-05-15 2004-11-25 Hemosol Lp Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
US11359004B2 (en) 2012-04-03 2022-06-14 William Schindler Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
AU693354B2 (en) * 1995-04-10 1998-06-25 Baxter International Inc. The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
US6149891A (en) * 1995-05-31 2000-11-21 Israel Humanitarian Foundation Ltd. X-ray contrast medium and method for protecting against harmful effects thereof
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US6911427B1 (en) 1995-09-15 2005-06-28 Duke University No-modified hemoglobins and uses therefore
UA64710C2 (en) * 1996-03-28 2004-03-15 Aqueous solution of polymerized hemoglobin (variants), method for its manufacture (variants) and method of infusion
US6547781B1 (en) * 1996-04-09 2003-04-15 Cynsure, Inc. Ultra-long flashlamp-excited pulse dye laser for therapy and method therefor
JP4583510B2 (en) * 1997-02-28 2010-11-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Methods and compositions for optimization of oxygen transport by cell-free systems
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
JP4038331B2 (en) * 1997-08-16 2008-01-23 オルソゲン アーゲー Methods for inducing proteins with therapeutic effects
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
US6347627B1 (en) * 1998-04-23 2002-02-19 Pioneer Inventions, Inc. Nitrous oxide based oxygen supply system
CA2266174A1 (en) * 1999-03-18 2000-09-18 Hemosol Inc. Hemoglobin-antioxidant conjugates
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
EP1233986A4 (en) * 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl Reduced side-effect hemoglobin compositions
DE10011163A1 (en) * 2000-02-28 2001-09-13 Ew Handels & Consulting Gmbh System for detection of albumin transport properties, induces targeted conformation changes in samples for electron spin resonance spectrometry for accurate early warning of changes in the patient or product
AU2001293064A1 (en) * 2000-09-26 2002-04-08 Georgetown University Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP3912206B2 (en) * 2002-07-05 2007-05-09 株式会社日立製作所 Fuel pump for in-cylinder direct fuel injection system
CA2492803C (en) * 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
WO2004037843A2 (en) * 2002-10-25 2004-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
CN100431602C (en) * 2003-01-29 2008-11-12 北原实验室有限公司 Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing
EP1620097A4 (en) * 2003-04-25 2008-03-05 Mitos Inc Prophylactic pretreatment with antioxidants
US7589107B2 (en) * 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
ZA200604403B (en) * 2003-11-20 2007-09-26 Othera Pharmaceuticals Inc Amelioration of macular degeneration and other ophthalmic diseases
WO2006127592A2 (en) * 2005-05-26 2006-11-30 Othera Pharmaceuticals, Inc. Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts
DE102005031206A1 (en) * 2005-07-01 2007-01-11 Rovi Gmbh & Co. Kosmetische Rohstoffe Kg Method for the examination of liposomes
WO2008021577A2 (en) 2006-01-24 2008-02-21 The Board Of Trustees Of The University Of Illinois Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20070197599A1 (en) * 2006-02-02 2007-08-23 Matier William L Hydroxylamines and derivatives as anti-angiogenic agents
US20070197593A1 (en) * 2006-02-22 2007-08-23 Matier William L Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) * 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
JP5697335B2 (en) 2006-11-07 2015-04-08 ザ ジェネラル ホスピタル コーポレイション Attenuation of vasoconstriction induced by vasoactive oxygen carriers
US20080200405A1 (en) * 2007-02-16 2008-08-21 Ghanshyam Patil Drug Resistance Reversal In Neoplastic Disease
CN101687786B (en) 2007-02-22 2013-05-22 奥特拉控股公司 Hydroxylamine compounds and methods of their use
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
EP2776047A4 (en) 2011-11-07 2015-07-22 Gen Hospital Corp Treatment of red blood cells
CN102559592B (en) * 2011-12-26 2014-04-16 四川农业大学 Method for building oxidative stress model of carp red blood cells
CA2904397C (en) * 2013-03-15 2019-12-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for the treatment of carboxyhemoglobinemia
AU2018304174A1 (en) 2017-07-18 2020-02-06 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
US10597597B1 (en) 2018-09-12 2020-03-24 Exxonmobil Research And Engineering Company Fuel high temperature antioxidant additive
US11136516B2 (en) 2018-12-07 2021-10-05 Exxonmobil Research And Engineering Company Motor gasoline with improved octane and method of use
US10808194B2 (en) 2018-12-07 2020-10-20 Exxonmobil Research And Engineering Company Fuel high temperature antioxidant additive
CN112546206A (en) * 2020-12-30 2021-03-26 云锦华彰(北京)生物科技有限公司 Preparation method of human hemoglobin oxygen carrier, product and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290252A2 (en) * 1987-05-05 1988-11-09 Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Gov. Her Pasteurizable, freeze-driable hemoglobin-based blood substitute

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959287A (en) * 1972-07-10 1976-05-25 Syva Company Ligand determination of spin labeled compounds by receptor displacement
DE2449885C3 (en) * 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4136093A (en) * 1976-04-23 1979-01-23 Biotest-Serum-Institut Gmbh Hemoglobin preparation with increased oxygen release
US4240797A (en) * 1977-10-18 1980-12-23 The Governing Council Of The University Of Toronto Assay for reserve bilirubin binding capacity
JPS6023084B2 (en) * 1979-07-11 1985-06-05 味の素株式会社 blood substitute
JPS5716815A (en) * 1980-07-02 1982-01-28 Ajinomoto Co Inc Oxygen transporting agent for artificial blood
US4563349A (en) * 1980-07-30 1986-01-07 Takeda Chemical Industries, Ltd. Superoxide dismutase, its immobilized form, and their production and use
JPS5739854A (en) * 1980-08-25 1982-03-05 Terumo Corp Hollow fiber type artificial lung building in heat exchanger
US4401652A (en) * 1980-12-31 1983-08-30 Allied Corporation Process for the preparation of stroma-free hemoglobin solutions
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4473494A (en) * 1983-05-04 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Preparation of stroma-free, non-heme protein-free hemoglobin
DE3328365A1 (en) * 1983-08-03 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen NEW DIAGNOSTIC AGENTS
US4831012A (en) * 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4622294A (en) * 1985-02-08 1986-11-11 Kung Viola T Liposome immunoassay reagent and method
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
DE3675588D1 (en) * 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
CA1244349A (en) * 1985-06-26 1988-11-08 Jen-Chang Hsia Purification of hemoglobin and modified hemoglobin by affinity chromatography
GB8522535D0 (en) * 1985-09-11 1985-10-16 Amersham Int Plc Contrast agent
GB8600582D0 (en) * 1986-01-10 1986-02-19 Ca Minister Nat Defence Purifying biological materials
EP0235526A3 (en) * 1986-01-29 1988-03-23 Leipziger Arzneimittelwerk GmbH Activated polymer solids and process for their manufacture
US5256397A (en) * 1986-03-07 1993-10-26 M.R.I., Inc. 2,2,5,5-tetrasubstituted-pyrrolidine-1-oxyl compounds useful as MRI agents
US5104641A (en) * 1986-03-07 1992-04-14 M.R.I., Inc. Nitroxide NMR contrast enhancing agents and their use in NMR imaging
US4834964A (en) * 1986-03-07 1989-05-30 M.R.I., Inc. Use of charged nitroxides as NMR image enhancing agents for CSF
US4959305A (en) * 1986-06-18 1990-09-25 Miles Inc. Reversible immobilization of assay reagents in a multizone test device
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
FR2602774B1 (en) * 1986-07-29 1990-10-19 Atta NOVEL POLYHYDROXYLATED AND PERFLUOROALKYLATED AMPHIPHILIC MOLECULES HAVING SURFACTANT PROPERTIES
US4911929A (en) * 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
DE3636590A1 (en) * 1986-10-28 1988-05-26 Braun Melsungen Ag BLOOD REPLACEMENT
US4863717A (en) * 1986-11-10 1989-09-05 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging
AU1107888A (en) * 1986-12-29 1988-07-27 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
ATE110954T1 (en) * 1988-01-29 1994-09-15 Peter H Proctor HAIR GROWTH STIMULATION WITH NITROXIDE AND OTHER RADICALS.
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
US5023072A (en) * 1988-08-10 1991-06-11 University Of New Mexico Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract
US5061688A (en) * 1988-08-19 1991-10-29 Illinois Institute Of Technology Hemoglobin multiple emulsion
US5149425A (en) * 1988-11-09 1992-09-22 Chembiomed, Ltd. Affinity supports for hemoperfusion
US5314681A (en) * 1988-12-23 1994-05-24 Nycomed Innovation Ab Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
US5080645A (en) * 1989-10-31 1992-01-14 Hanig Joseph P Procedure for reducing the body burden of HIV (AIDS) and other blood borne infections
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
WO1991013619A1 (en) * 1990-03-16 1991-09-19 The United States Of America, Represented By The Secretary, United States Department Of Commerce Nitroxides as protectors against oxidative stress
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5114932A (en) * 1990-11-30 1992-05-19 Runge Thomas M Hyperosmolar oxyreplete hemosubstitute
US5290919A (en) * 1992-08-28 1994-03-01 The University Of Maryland Baltimore Hemoglobin intramolecularly cross-linked with trivalent reagents
US5407657A (en) * 1992-09-22 1995-04-18 Unger; Evan C. Hybrid magnetic resonance contrast agents
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5494030A (en) * 1993-08-12 1996-02-27 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen in biological systems
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290252A2 (en) * 1987-05-05 1988-11-09 Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Gov. Her Pasteurizable, freeze-driable hemoglobin-based blood substitute

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H.M. MCCONNELL ET AL.: "SPIN-LABELLED HAEMOGLOBIN AND THE HAEM-HAEM INTERACTION.", NATURE., vol. 220, 23 November 1968 (1968-11-23), LONDON GB, pages 787 - 788 *
R.J. MEHLHORN ET AL.: "NITROXIDE-STIMULATED H2O2 DECOMPOSITION BY PEROXIDASES AND PSEUDOPEROXIDASES.", FREE RADICAL RESEARCH COMMUNICATIONS, vol. 17, no. 3, 1992, LONDON, GB, pages 157 - 175 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605619B1 (en) 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
WO1996029974A3 (en) * 1995-03-31 1997-03-27 Hsia Jen Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
EA000618B1 (en) * 1995-03-31 1999-12-29 Синзим Текнолоджиз, Инк. Compositions and methods utilizing nitroxydes in combination with biocompatible macromolecules
AU714661B2 (en) * 1995-03-31 2000-01-06 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
JP2008074876A (en) * 1995-03-31 2008-04-03 Synzyme Technologies Inc Composition using both nitroxide and biocompatible polymer, and method
WO1996029974A2 (en) * 1995-03-31 1996-10-03 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
SG95590A1 (en) * 1995-03-31 2003-04-23 Synzyme Technologies Inc Compositions and method utilizing nitroxides in combination with biocompatible macromolecules
DE19514088A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate for the treatment of inflammation, infection and / or skin diseases
WO1996040127A1 (en) * 1995-06-07 1996-12-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nitroxides as protectors against oxidative stress
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
WO1998034955A1 (en) * 1997-02-06 1998-08-13 Duke University Medical Center No-modified hemoglobins and uses therefor
EP1029551A3 (en) * 1999-02-08 2001-03-07 Hokkaido University Nitrogen monoxide metabolite-polyoxyalkylene-hemoglobin complex
US6667292B1 (en) 1999-02-08 2003-12-23 Hokkaido University Nitric monoxide metabolite-polyoxyalkylene-hemoglobin complex
EP1029551A2 (en) * 1999-02-08 2000-08-23 Hokkaido University Nitrogen monoxide metabolite-polyoxyalkylene-hemoglobin complex
WO2004100995A1 (en) * 2003-05-15 2004-11-25 Hemosol Lp Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
US11359004B2 (en) 2012-04-03 2022-06-14 William Schindler Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins

Also Published As

Publication number Publication date
CN1046635C (en) 1999-11-24
EP0714407B1 (en) 1998-02-11
TW529949B (en) 2003-05-01
CN1133050A (en) 1996-10-09
JPH09501681A (en) 1997-02-18
ATE163186T1 (en) 1998-02-15
HK1007858A1 (en) 1999-04-23
US6048967A (en) 2000-04-11
DK0714407T3 (en) 1998-09-28
DE69408539D1 (en) 1998-03-19
CA2169178A1 (en) 1995-02-23
EP0770627A1 (en) 1997-05-02
EP0714407A1 (en) 1996-06-05
US5591710A (en) 1997-01-07
CN1229677A (en) 1999-09-29
DE69408539T2 (en) 1998-06-18
TW381022B (en) 2000-02-01
US5789376A (en) 1998-08-04
CN1228962A (en) 1999-09-22
JP3628019B2 (en) 2005-03-09
ES2114227T3 (en) 1998-05-16
US6323175B1 (en) 2001-11-27
US5811005A (en) 1998-09-22
GR3026609T3 (en) 1998-07-31

Similar Documents

Publication Publication Date Title
US5591710A (en) Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
AU714661B2 (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US6458758B1 (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
Tsuchida et al. Artificial oxygen carriers, hemoglobin vesicles and albumin− hemes, based on bioconjugate chemistry
US5807831A (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
Harris et al. Modern cross‐linking strategies for synthesizing acellular hemoglobin‐based oxygen carriers
US6864094B2 (en) Method of preserving oxygen infusions
JP2008074876A (en) Composition using both nitroxide and biocompatible polymer, and method
Chang The use of modified hemoglobin as an oxygen carrying blood substitute
TW492866B (en) A pharmaceutical composition for treatment or diagnosis of ischemia reperfusion injury
Sakai et al. Solution to the problems of acellular hemoglobins by encapsulation and the intrinsic issues of hemoglobin vesicles as a molecular assembly
JP2006036748A (en) Artificial oxygen carrier containing methemglobin formation inhibitor
Winslow et al. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. Volume 22, Number 3, 1994.
Quebec Crosslinked hemoglobin-superoxide dismutase-catalase and methemoglobin formation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193809.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN DE GB JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2169178

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994927922

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994927922

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994927922

Country of ref document: EP